Podcasts about ut southwestern

Listen to JCO's Art of Oncology article, "A Fight Bigger Than Myeloma” by Dr. Adeel Khan, an Assistant Professor of Medicine and Public Health at UT Southwestern. The article is followed by an interview with Dr. Adeel Khan and host Dr. Mikkael Sekeres. Dr. Khan shares the story of a patient whose multiple myeloma diagnosis and treatment serves as a reminder of the civil liberties progress we've made and that we have more to go. TRANSCRIPT Narrator: A Fighter Bigger Than Myeloma, by Adeel M. Khan, MD, MPH, MS  I met her during the early part of my clinical training in hematology/oncology. She was in her late 70s, dressed in a rust-colored cardigan and a headwrap with patterns that reminded me of Ghanaian kente cloth. Her eyes were sharp, her tone polite but direct. You could tell from the moment she spoke that she had lived a life where she had to advocate—for herself, for her family, for her place in rooms that were not always welcoming.  Her chart said “multiple myeloma, R-ISS II,” but it did not say that she had first come to an emergency room at least a year earlier complaining of back pain and fatigue and had been told it was probably arthritis or old age. It did not mention that she had seen three different doctors before someone ordered the laboratory tests that finally began to work up her anemia and increasingly compromised kidney function. It would take another trio of doctors to eventually order a magnetic resonance imaging whose ghostly lytic lesions led down the path to a bone marrow biopsy and her cancer diagnosis. When I brought this up gently during one of our early appointments, she looked at me and said, “They don't hear pain the same when it comes from someone like me.” As a Black woman from the Deep South, she had grown up learning how to navigate a health care system that did not always believe her. She told me stories about being dismissed, misdiagnosed, and interrupted. She was born into an era of structural violence where she would be ignored at best and mistreated at worst. She carried the weight of those moments, but she also carried strength, and clarity, and the kind of dignity that made people sit up straighter in their leather chairs when she entered the room. She was one of the most quietly revolutionary people I have ever known, having grown up during a time of civil rights activism. She had even taken part in bending Dr King's long arc of the moral universe toward justice and could share story upon story from her glory days. Her myeloma treatments were not easy. Chemotherapy rarely is. She shared that there were days when her body was tired of fighting, when her bones ached, her blood counts dropped, and her neuropathic pain throbbed. In the back of my mind, I thought how tragic it was that her delayed diagnosis added unnecessary complications and whether she too thought of that. She was fully mindful of the issues people with her skin color faced in our American healthcare system and society as a whole and revealed how that motivated her to carry forward. “If I don't take up space here,” she told me once, “then someone else like me won't either.” Over the course of our visits, I came to understand that she did not see her myeloma as the hardest fight of her life. Not by a long shot. Her primary struggle was centered on life in Birmingham in the 1950s where separate but equal was still the law of the land; her mother cleaned houses, her father worked odd jobs, and her own prospects were uncertain. She admired the writings of Richard Wright and Jean Toomer and was not shy in sharing her passions. One day, during a particularly tough visit—her disease had progressed and we were down to limited options—I found myself meandering. We went through the usual workup and discussions: laboratory test results, symptoms, and treatment options. I offered the prospect of clinical trials, but she shook her head gently and said, “I've done my time in experiments—I can't give myself to a system that gave my people so little.” I paused. It was the first hint of what would become a larger conversation—not just about medicine, but about history. She was well aware of the atrocities of the Tuskegee syphilis trials in her home state, the Kligman experiments on incarcerated Black men, and the forced sterilization of women of color. As dependent upon medicine as she was in her old age, it carried a bloody stain of dehumanizing racism that soured her against it. Outwardly, I had little in common with her. As a young South Asian man growing up in times more conscious of racial injustice, I was far removed from these historical crimes. Although I learned of them during my education, I did not internalize their impact on the patients in front of me in clinic. But through her I came to comprehend just how scarring and enduring these events can be and how they can rob someone of trust. And the truth is the health care system had not treated her well. She had personal stories of doctors who did not believe her pain, nurses who assumed she was uneducated,  and being passed over for better options, better care, and better answers. “But I kept showing up,” she said. “Because that's what we do. We show up even when we're not wanted.” Her stories to me were revelations. In her younger years, she had helped organize teachers at her school when they tried to fire a fellow Black teacher who seemingly spoke too loud in a meeting. She had lived through redlining, through the crack epidemic, through watching young Black men vanish into prisons, and still she rose every day and worked as a public school teacher for decades. She worked for a system that largely did not work for her. I came to admire that about her—that in simply living day-to-day life with plain dignity and acute awareness of society's issues, she promoted change by living it. “You want to talk about cancer?” she once said, half laughing. “Try walking into a bank in 1972 with a good credit score and a Black face. That's a disease this country still hasn't cured.” Curiously, she did not say these things with bitterness. Not even anger, really. Just clarity. Like someone who had long ago made peace with the truth, even if it was sharp. In clinic, she challenged my every assumption—about treatment tolerance, about compliance, about who is difficult, and who is “advocating.” And she taught me to look differently at the ways bias lingers in medicine. Not just in data or policies, but in subtle moments: the tone we use when explaining options, the hesitations in our tests and referrals, and the assumptions we may not even realize we are making. And she did not just expect good care—she demanded it. She told me early on, “Don't you treat me like I'm anything other than your mother.” That landed. And in seeing patients before me now, I remind myself to wonder who they were in their past lives, what baggage burdens them, and how it all shapes their perspectives. So from my view, she fought multiple myeloma with everything she had, but from hers, she fought something bigger: an entire system shaped by inequality. And ultimately, she made me better to realize that, not just as a doctor, but as a human being. In my years since knowing her, completing my training, and beginning my practice, I reflect on her grace. I think not just about her life, but what it means to practice medicine in a world that often forgets what patients carry with them into the clinic—generations of weight, of injustice, of strength. Mikkael Sekeres: Welcome back to JCO's Cancer Stories, The Art of Oncology. This ASCO podcast features intimate narratives and perspectives from authors exploring their experiences in oncology. I'm your host, Mikkael Sekeres. I'm Professor of Medicine and Chief of the Division of Hematology at the Sylvester Comprehensive Cancer Center, University of Miami. I am so happy that today we are joined by Adeel Khan, who's Assistant Professor of Medicine and Public Health at UT Southwestern in Dallas to talk about his Journal of Clinical Oncology article, “A Fight Bigger than Myeloma.” Our guest's disclosures will be linked in the transcript. Adeel, thank you so much for contributing to JCO and for joining us to discuss your article. Adeel Khan: Thank you so much for having me. It's a pleasure to be here. Mikkael Sekeres: Adeel, I don't want to be disingenuous to our readers by acting as if we've just met. You and I have known each other for a decade since you were still in your training. I wonder if for our listeners you can tell us a little bit about yourself, where are you from and and walk us through your career so far. Adeel Khan: More than happy to. So, I grew up mostly in Oklahoma, but I've sort of lived around in the Northeast and here in the Southwest where I am currently. I did college at the University of Oklahoma. I did medical school at the University of Michigan. I did residency with good fortune at the Cleveland Clinic where I happened to get to know you and have continued to know you since. I did my fellowship then in hematology oncology at Beth Israel Deaconess in the Harvard system and along the way of all that I did a Masters of Public Health at Harvard and a Masters of Science and Epidemiology at Columbia, and that pinball finally settled here to UT Southwestern here in Dallas which I am very happy to make my second home. Mikkael Sekeres: That's great. I will say just for our listeners you've been a superstar since the moment you were a resident. It's been a real treat for me to get to know you over the years. Adeel Khan: Thank you so much. Mikkael Sekeres: Can you tell us a little bit about your own story as a writer? You're a good writer. We get submissions from some really good writers every single week. It's a real privilege to be an editor for the Art of Oncology section and it's always reinvigorating to me to see how many good writers there are in medicine. How did you start your journey as a writer and how long have you been writing reflective narrative pieces? Adeel Khan: I would say if I went back to let's say high school, you know, people tend to be divided into kind of like the sciency types versus the literary arts types and you're kind of an either/or, you know, you didn't really have as much crossover then. But you know, I actually didn't mind when we had an essay due and I liked writing back then, and when I entered college I did a minor in English because I actually did enjoy that and I just liked the idea of being able to put your thoughts on paper in a way immortalizing them. Adeel Khan: And then as I sort of pursuing medicine more and more, publishing is really- it has all kinds of flavors to it and scientific publishing is obviously what has been emphasized, but you know, there's so many things to talk about within medicine. There's the science and the art of the field, and as I've moved along, I've written different pieces focusing really on patient stories and interactions. And I think my motivation has always been that as I have gotten particularly nowadays increasingly busy, I've had the fortune and misfortune of becoming more and more busy, it's easy to lose the opportunity to really connect with people that makes what we do meaningful. And so in those times when you know, and they can be rare, but when you really get to connect with someone in front of you who you're helping to care for, it's really refreshing and it's rejuvenating and I've tried to keep that with me as long as I can as I've gone through my journey. Mikkael Sekeres: There's a lot of jumping off points from what you just said, Adeel. I wonder if I can start with do you consider yourself an English major who's good at science or do you consider yourself a scientist who's a good writer? Adeel Khan: I think I'm too humble to say either. I think I was really a science major who just happened to like writing and reading and kept that as a part of myself. Mikkael Sekeres: Because I think there are a cadre of doctors who are actually English majors and have learned to turn science into storytelling and that's their entrée into science and medicine. I remember I talked for a while with David Scadden about this. He's a brilliant translational scientist who's based at Mass General who also teaches a writing course to the Harvard undergrads and who was an English major when he was an undergrad at Case Western. We've talked about this, about how there are people, I'll include myself in this, who just think different, who probably have these liberal arts brains and they figured out a way to convert science into a way a liberal arts person can understand it. Adeel Khan: Yeah, I mean narrative medicine has been I think around all along and it has only kind of been recently named as a field, but I mean it very much speaks to that that there's so much more than just G proteins in medicine. Mikkael Sekeres: I'm thrilled to hear that by the way. You mentioned you were an English minor. Are there particular writers who are an influence on you or can you talk about what's the most recent book or article you've read? Adeel Khan: Oh, that is a great question. Paulo Coelho is someone I've liked for a long time, The Alchemist. I really liked it because I read it after I had lived in Egypt. I lived in Egypt between college and med school as a study abroad program, and I had actually been to the Faiyum Oasis where the protagonist in that story ends up. And so it was just a fascinating story to me that I could trace some of the steps that are discussed in the book and it's so much- it's a story about self discovery which at that phase of life that I was in was you know, very much a theme of my own life. And so that's one that definitely stands out in my head. Mikkael Sekeres: Do you think reading pieces outside of medicine makes you a better scientist? Adeel Khan: I think absolutely. I think it makes you a better human being. In some ways I lament that so much of what I do reading now is so much just about what's in the field, what's new in myeloma, what's new in hematology oncology and I sort of miss the escape to reading other things and being able to pursue it. And even broader than just what a novel really offers. I mean, I grew up reading comic books too and I've always loved superheroes and fiction whether it's Star Wars and other things. And really they're just stories and the medium- there might be connotations whether it's a comic book or a or a novel, but they're just different mediums, but the fact that they're just stories is fundamental. I actually think to myself that it's so fascinating that the earliest piece of writing that we've really retained as human beings is we believe, the Epic of Gilgamesh, which is really a story of a superhero when you think about it, you know, and it's it's fiction, it's phantasmic in so many ways. But it speaks to how stories are just vital as people. Mikkael Sekeres: And what is it about graphic novels or my kids now of course call them graphic novels. We're not allowed to call them comic books. Adeel Khan: As they've been renamed, yeah. Mikkael Sekeres: What is it about graphic novels or comic books or the story of a hero that appeals to us in medicine? Adeel Khan: I think it's in some ways a parable of what we're doing. There's something so powerful and fundamental about this idea of good-evil and we can rename it in different ways, but that you're trying to overcome something that's an issue, an obstacle. And when you think about what we do in- particularly in oncology, that's very much what we're trying to do. We're trying to overcome an illness, a disease, to try to help the person in front of us. And it has different aspects to it. It could be someone pursuing something in a lab, it can be treating someone in front of you in clinic, but that simple dichotomy of there's something good about what you're doing because there's something bad in front of you is just the fundamental that runs through it all. Mikkael Sekeres: It's fascinating. I wonder if 30, 40, 50 years ago people would have said, “Oh, it's because the doctor is the hero,” but we don't view ourselves that way anymore. The patient is the hero. I love how you posit this as a good versus evil, the evil of course being cancer and the good everything that our patients do and that we try to to help to do to overcome that. Adeel Khan: For sure. Mikkael Sekeres: You wrote a really great essay about a woman who was a patient of yours. Can you tell me a little bit about what inspired you this time to make this connection and to write about this woman? Adeel Khan: Within the past year or so as I had been just really- the fortune and misfortune of getting busier, I lamented that I just wasn't able to spend as much time with patients in the way that I used to. One of the beauties of medical school and you know, to some degree residency and certainly fellowship is that you just have a little bit more time as a trainee, student and trainee where you can really bond with your patients I think a little bit more. And so in trying to kind of refresh my motivation, I was thinking about just kind of randomly some stories that I've kept in the back of my mind and this patient's story is one that stood out to me as I was recalling things. It was so fascinating to me because she had the disease which I now focus on. And the way that she viewed it and the way that she viewed it as a part of her life was just so different than what I think most people think of. And in that way it was very revitalizing that her focus in her life was part of a broader theme of the way that I think she viewed society. And this was just one piece of her own part of that much, much larger puzzle. Mikkael Sekeres: You really write lovingly about her and about how meaningful her context was in how you cared for her and what her experience was in the medical system. I wonder if I can read a little bit of what you wrote because it really did grab me as well. I'm going to start out by quoting you where you say, “Outwardly, I had little in common with her. As a young South Asian man growing up in times more conscious of racial injustice, I was far removed from these historical crimes. Though I learned of them during my education, I did not internalize their impact on the patients in front of me in clinic. But through her, I came to comprehend just how scarring and enduring these events can be and how they can rob someone of trust.” Wow, there's a lot there. Could you start with what was your perspective as a young South Asian man growing up in Oklahoma and what your view was of racial injustice compared to what her experience was of racial injustice? Adeel Khan: Yeah, I have to admit I don't know that I thought that much of it back then and I think that that's part of what it is. You know, being someone who was South Asian, I'm Pakistani, I have Indian roots, and coming into American history and as we learned about it there's so much about slavery and the theme of slavery unfortunately and and the struggles that enslaved peoples have. And you know, as a relatively recent immigrant, I didn't see myself in that narrative. I didn't see myself in that historical reality. But I knew about it intellectually, you know, I knew about the Tuskegee Syphilis Experiments, you know, I learned about all these things and and you learned about how atrocious so much of it is. But again, not being so directly connected, I did not put myself in that same role as someone to view it so close to myself. I will say it hit a little bit more after 9/11 when you know, I was randomly stopped at airport security a little bit more often in those days and again, I think that speaks to racial injustices, you know, I was certainly profiled looking back then, I've been held by TSA in the past, but even that is very minor compared to what African Americans have dealt with here. And this patient in just kind of sharing her tidbits during our time together, I was not directly asking her so much of this. She was really offering a lot of it to me as we would talk and she would be very generous in sharing parts of her story. And over time I kind of understood the broader narrative of her life. You know, it was clear how much of all that was actually in the forefront of her head. Adeel Khan: And I think she might have been a little bit more unique in the way that she kept it there, but she was hyper vigilant of issues of society and the roots that brought a given society to where it is here. I kind of got to know her, this is during the COVID pandemic and this was after the injustice of what happened to George Floyd and so it was a theme that I think people were talking about more and so I think she felt comfortable in saying really what was quite a bit that was stewing in the back of her head seemingly at all times. Mikkael Sekeres: It's so interesting you talk about what you endured after 9/11 as being, I'm going to quote you now, “minor” compared to what she's been through, but even a minor affront like that can really compromise your trust. You write about her, “As a Black woman from the deep South, she had grown up learning how to navigate a healthcare system that did not always believe her.” Can you expand on that a little bit? How is it that the healthcare system didn't believe her and what can we do going into interactions with patients from different backgrounds where we're incorporating that there's a compromise of trust and we have to make up for that? Adeel Khan: Yeah, and I think you know, it's so unfortunate that so many people have stories like this where, in her case really it was back pain that was her presenting symptom. This is long before she knew me. And she'd had the back pain for quite some time, but being an older woman, she was in her 70s at that time, she was not in phenomenal health for other reasons. It sounds like she was just kind of ignored, told that it was old age, tendon changes, she did not have meaningful imaging for some time. When she finally did after seeing a slew of different providers, that's when it was revealed like there's something more significant here. And then when you kind of piece that a little bit retrospectively and I think she certainly sensed this and I did when I- hindsight's always 20/20, when I looked through things, it's like, well, this probably could have been caught much earlier. It's just that no one really I think listened to what she was speaking to with her pain and the gravity that was actually behind it. And it just speaks to the fact that I think we have to be more thoughtful in what we take away from patients and not to ignore even small comments because they might be revealing of something much bigger behind them. Mikkael Sekeres: You quote her, you have some really great quotes in your essay where you just listen to what she says and transcribe it because what she says is very meaningful. And one of the quotes you provide from her is, “They don't hear pain the same when it comes from someone like me.” Wow. “When it comes from someone like me,” someone like her, how was it that people weren't hearing her description of pain, something that was different that was going on in her body and how can we be more attentive to people when they complain about things like pain? Adeel Khan: It's unfortunate that there's even known data to show how depending upon a patient's melanin content in their skin, how likely they are to get pain medications and what happens to them is different and this is an unfortunate example of that where I think she just wasn't heard properly. And so it wasn't addressed properly and she was not shy about saying that. I mean I think she sensed that. She was very clear in feeling that herself and in wanting to have better care, she was still prevented and hence why she had to go from provider to provider. Mikkael Sekeres: You've lived in a bunch of different places in the country. I mean, following your path, you've been in Oklahoma, you've been in Michigan, Ohio, Massachusetts, and now Texas. Do you think that we as providers have to have different levels of sensitivity depending on where in the country we're practicing and how some of our patients' trust in healthcare may have been compromised in those different parts of the country? Adeel Khan: I think absolutely. I mean this particular patient was from Alabama which has a heavy history that she was again very aware of and for those of us reading history books are also very aware of too. And it's interesting how, while the U.S. is in some ways- has some aspects that are monolithic, but it's very much not so. It's very patchy and people are different, you know, if I take one theme that we're talking about here is obviously racial injustice, but if you take something like obesity, you know, prevalence rates are very different throughout the country and attitudes surrounding it are also very different. And I think we do- ought to be mindful that in treating the patient in front of us, it's not done without context. And so how they view their illness and their situation is going to be different depending upon the state, depending upon the city, depending upon actually even the era that they grew up in. So I would say now, if you took actually a similar patient, but you put her in a very modern context post-year 2000, she's likely to have different feelings of the situation around her than someone who was born in this case in the 1940s. And that just speaks to the fact that circumstances change and we should be recognizing that as providers, even though it's not always easy to. Mikkael Sekeres: Well, it just emphasizes how very important it is to know the history of the place where we practice and how it's affected our patients' perceptions of healthcare and trust and being cared for, particularly now as there's such a movement to whitewash that history and eliminate it from major institutions like the Smithsonian. It has been such a pleasure to have Adeel Khan here. He is Assistant Professor of Medicine, Public Health at UT Southwestern in Dallas and wrote just a great JCO article called “A Fight Bigger Than Myeloma.” Adeel, thank you so much for submitting your article and for joining us today. Dr. Adeel Khan: Thank you so much for having me. It's been a pleasure. Mikkael Sekeres: If you've enjoyed this episode, consider sharing it with a friend or colleague or leave us a review. Your feedback and support helps us continue to have these important conversations. If you're looking for more episodes and context, follow our show on Apple, Spotify, or wherever you listen and explore more from ASCO at ASCO.org/podcasts. Until next time, this has been Mikkael Sekeres for JCO Cancer Stories: The Art of Oncology. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Show Notes Like, share and subscribe so you never miss an episode and leave a rating or review.  Guest Bio: Dr Adeel Khan is an Assistant Professor of Medicine and Public Health at UT Southwestern.

Kidney cancer management is evolving. How are experts adapting? In this installment of BackTable Tumor Board, Dr. Brandon Manley (Urologic Oncology, Moffitt Cancer Center), Dr. Raquibul Hannan (Radiation Oncology, UT Southwestern), and Dr. Rana McKay (Medical Oncology, UC San Diego) join guest host Mark Ball (Urologic Oncology, National Cancer Institute) to share their multidisciplinary perspectives on challenging, real-world kidney cancer cases.---This podcast is supported by:Ferring Pharmaceuticalshttps://ad.doubleclick.net/ddm/trackclk/N2165306.5658203BACKTABLE/B33008413.420220578;dc_trk_aid=612466359;dc_trk_cid=234162109;dc_lat=;dc_rdid=;tag_for_child_directed_treatment=;tfua=;gdpr=${GDPR};gdpr_consent=${GDPR_CONSENT_755};gpp=${GPP_STRING_755};gpp_sid=${GPP_SID};ltd=;dc_tdv=1---SYNPOSISThe conversation covers diagnostic dilemmas, navigating the treatment options of surgery, systemic therapy, and radiation, and the importance of a multidisciplinary approach. Through detailed case reviews, the panel highlights practical pearls, emerging clinical trials, and collaborative approaches that exemplify modern kidney cancer care.---TIMESTAMPS0:00 - Introduction02:20 - Case 1 (Incidental Renal Mass)16:52 - Case 2 (Bilateral Renal Masses)37:22 - Case 3 (Locally Advanced Renal Mass)56:34 - Case 4 (Symptomatic, Metastatic Disease)01:14:00 - Final Takeaways

In this episode, Dr. Madhuri Sopirala, Medical Director and Chief of Infection Prevention at Parkland Health and Chair of SHEA's Infection Prevention and Control Burn Unit Special Interest Group, moderates a timely conversation on the unique challenges of infection prevention in burn units. She is joined by Dr. Samuel Mandell, Associate Professor of Surgery at UT Southwestern and Director of the Parkland Regional Burn Center, and Dr. David Weber, Distinguished Professor of Medicine and Medical Director of Infection Prevention at UNC Medical Center, as well as current SHEA Board of Trustees President. Together, they explore why burn units require specialized approaches to infection prevention, the nuances of distinguishing outbreaks from baseline infection risks, and strategies for optimizing burn unit design to improve patient safety. The discussion also highlights often-overlooked vectors of infection, emerging research priorities, and what the future may hold for advancing infection prevention in burn care.

Sean Morrison, Ph.D., from the Children's Medical Center Research Institute at UT Southwestern, investigates how stem cells function, regenerate, and interact with their surrounding environment in the bone marrow. His research reveals how leptin receptor-positive cells—key components of the bone marrow niche—regulate hematopoietic stem cell maintenance and regeneration, influence platelet production, and respond to physiological stress like pregnancy. Morrison uncovers a reciprocal relationship between these niche cells and peripheral nerves, showing that disrupting nerve signals impairs bone marrow recovery after chemotherapy or radiation. His work also links retrotransposon activation during pregnancy to increased red blood cell production, with implications for maternal health and transplant medicine. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40449]

Sean Morrison, Ph.D., from the Children's Medical Center Research Institute at UT Southwestern, investigates how stem cells function, regenerate, and interact with their surrounding environment in the bone marrow. His research reveals how leptin receptor-positive cells—key components of the bone marrow niche—regulate hematopoietic stem cell maintenance and regeneration, influence platelet production, and respond to physiological stress like pregnancy. Morrison uncovers a reciprocal relationship between these niche cells and peripheral nerves, showing that disrupting nerve signals impairs bone marrow recovery after chemotherapy or radiation. His work also links retrotransposon activation during pregnancy to increased red blood cell production, with implications for maternal health and transplant medicine. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40449]

Sean Morrison, Ph.D., from the Children's Medical Center Research Institute at UT Southwestern, investigates how stem cells function, regenerate, and interact with their surrounding environment in the bone marrow. His research reveals how leptin receptor-positive cells—key components of the bone marrow niche—regulate hematopoietic stem cell maintenance and regeneration, influence platelet production, and respond to physiological stress like pregnancy. Morrison uncovers a reciprocal relationship between these niche cells and peripheral nerves, showing that disrupting nerve signals impairs bone marrow recovery after chemotherapy or radiation. His work also links retrotransposon activation during pregnancy to increased red blood cell production, with implications for maternal health and transplant medicine. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40449]

Sean Morrison, Ph.D., from the Children's Medical Center Research Institute at UT Southwestern, investigates how stem cells function, regenerate, and interact with their surrounding environment in the bone marrow. His research reveals how leptin receptor-positive cells—key components of the bone marrow niche—regulate hematopoietic stem cell maintenance and regeneration, influence platelet production, and respond to physiological stress like pregnancy. Morrison uncovers a reciprocal relationship between these niche cells and peripheral nerves, showing that disrupting nerve signals impairs bone marrow recovery after chemotherapy or radiation. His work also links retrotransposon activation during pregnancy to increased red blood cell production, with implications for maternal health and transplant medicine. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40449]

Sean Morrison, Ph.D., from the Children's Medical Center Research Institute at UT Southwestern, investigates how stem cells function, regenerate, and interact with their surrounding environment in the bone marrow. His research reveals how leptin receptor-positive cells—key components of the bone marrow niche—regulate hematopoietic stem cell maintenance and regeneration, influence platelet production, and respond to physiological stress like pregnancy. Morrison uncovers a reciprocal relationship between these niche cells and peripheral nerves, showing that disrupting nerve signals impairs bone marrow recovery after chemotherapy or radiation. His work also links retrotransposon activation during pregnancy to increased red blood cell production, with implications for maternal health and transplant medicine. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40449]

Sean Morrison, Ph.D., from the Children's Medical Center Research Institute at UT Southwestern, investigates how stem cells function, regenerate, and interact with their surrounding environment in the bone marrow. His research reveals how leptin receptor-positive cells—key components of the bone marrow niche—regulate hematopoietic stem cell maintenance and regeneration, influence platelet production, and respond to physiological stress like pregnancy. Morrison uncovers a reciprocal relationship between these niche cells and peripheral nerves, showing that disrupting nerve signals impairs bone marrow recovery after chemotherapy or radiation. His work also links retrotransposon activation during pregnancy to increased red blood cell production, with implications for maternal health and transplant medicine. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40449]

What happens when we trade case law for cancer care? You get one of the richest, most human conversations we've ever brewed.This week on Counsel Brew, we branch out beyond the courtroom and into the clinic with Dr. Richard Hall—a thoracic oncologist whose life's work is treating lung cancer and supporting patients through some of their toughest moments.A proud Texan and graduate of Texas A&M and UT Southwestern, Rick went on to train at the University of Virginia and the H. Lee Moffitt Cancer Center before returning to UVA, where he not only treats patients but also trains the next generation of oncologists. He's earned teaching awards, led UVA's fellowship program, and advanced cutting-edge research in immunotherapy, targeted therapies, and combination treatments.But beyond the credentials lies a doctor who knows that medicine is about people first. In this conversation, Rick opens up about: ☕ The emotional reality of delivering difficult news and how empathy and communication are as vital as any treatment. ☕ The evolution of lung cancer care, from chemotherapy to immunotherapy to antibody-drug conjugates (a “guided missile” approach to attacking tumors). ☕ Why collaboration among medical teams is just as important as collaboration in business or law. ☕ His personal journey from med school to oncology and the moments that shaped his calling.And because no Counsel Brew is complete without actual brew, we lighten things up with Rick's adventures as a self-taught barista—how chasing the perfect shot of espresso demands scientific precision in measurements and pressure—his favorite lattes, and the joy of finding balance through coffee.

In this episode of the SRNA "Ask the Expert" podcast moderated by Dr. GG deFiebre, Dr. Kyle Blackburn and Dr. Benjamin Greenberg discussed the need for updated diagnostic criteria for myelitis. Dr. Blackburn explained the term myelitis and the importance of precise terminologies for accurate diagnoses and research [00:05:10]. Dr. Greenberg elaborated on the advancements in testing and understanding of associated disorders like NMOSD and MOGAD since 2002 [00:11:10]. Both experts stated that the shift from "transverse myelitis" to "myelitis" will aid future research, treatments, and patient care [00:17:27]. They reassured patients that these changes would essentially refine their care but not alter it dramatically [00:23:40]. They encouraged patients to stay informed and communicate with their healthcare providers about these updates [00:28:58].Kyle Blackburn, MD is an Assistant Professor in the Department of Neurology at UT Southwestern Medical Center in Dallas, Texas. He specializes in neuroimmunology and has clinical interests in antibody-mediated neurologic disorders, including autoimmune encephalitis, epilepsy, and ataxias; neurologic complications of cancers, including paraneoplastic disorders and checkpoint inhibitor/CAR T-cell toxicity; and demyelinating disorders, including sarcoidosis, neuromyelitis optica, myelin oligodendrocyte glycoprotein (MOG)-associated disease, and multiple sclerosis. Dr. Blackburn earned his medical degree at the University of Kentucky College of Medicine. He performed his residency in adult neurology at UT Southwestern, serving his final year as Chief Resident, and stayed to complete a fellowship in neuroimmunology, during which he earned the James T. Lubin Clinician Scientist Award from the Siegel Rare Neuroimmune Association (SRNA). He joined the UT Southwestern faculty in 2020.Benjamin M. Greenberg, M.D., M.H.S. is a Professor and the Cain Denius Scholar in Mobility Disorders in the Department of Neurology at UT Southwestern Medical Center in Dallas, Texas. He currently serves as the Vice Chair of Translational Research and Strategic Initiatives for the Department of Neurology. He is also the interim Director of the Multiple Sclerosis Center and the Director of the Neurosciences Clinical Research Center. In addition, he serves as Director of the Transverse Myelitis and Neuromyelitis Optica Program and the Pediatric Demyelinating Disease Program at Children's Medical Center.Dr. Greenberg earned his medical degree at Baylor College of Medicine before completing an internal medicine internship at Chicago's Rush Presbyterian-St. Luke's Medical Center. He performed his neurology residency at the Johns Hopkins School of Medicine. He also holds an M.H.S. in molecular microbiology and immunology from the Bloomberg School of Public Health, as well as a bachelor's degree in the history of medicine – both from Johns Hopkins. Prior to his recruitment to UT Southwestern in 2009, Dr. Greenberg was on the faculty of the Johns Hopkins Division of Neuroimmunology, serving as the Director of the Encephalitis Center and Co-Director of the nation's first dedicated Transverse Myelitis Center.Dr. Greenberg splits his clinical time between adult and pediatric patients at William P. Clements Jr. and Zale Lipshy University Hospitals, Parkland, and Children's Medical Center. His research focuses on better diagnosing, prognosticating, and treating demyelinating diseases and nervous system infections. He also coordinates clinical trials to evaluate new treatments to prevent neurologic damage and restore function to affected patients. 00:00 Introduction00:58 Overview of Myelitis and Diagnostic Criteria02:57 Historical Context and Importance of Updated Criteria05:10 Challenges with Current Terminology11:10 Changes in Understanding and Diagnostic Approaches17:27 Implications for Patients and Clinical Practice23:40 Impact on Research and Future Directions28:58 Patient Advocacy31:17 Conclusion

The toolbox for vessel preparation is rapidly expanding. Are you keeping up? In this episode, host Dr. Sabeen Dhand is joined by Dr. Jay Matthews, interventional cardiologist (Manatee Memorial Hospital) and Dr. Michael Siah, vascular surgeon (UT Southwestern), to explore the latest innovations and strategies in vessel prep. --- This podcast is supported by: Cagent Vascularhttps://cagentvascular.com/ --- SYNPOSIS The discussion opens with a look at new additions to their practice over the past few years, including bioresorbable scaffolds for below-the-knee interventions and retrievable stent technologies. Both experts emphasize the role of imaging—particularly CT angiography and IVUS—and discuss how renal disease impacts their use of contrast during diagnosis and intervention. They then walk through how they assess vessels on angiography or IVUS to decide when and where to use specialty tools. From intravascular lithotripsy for managing dense calcification to serration angioplasty, the conversation highlights how the doctors decide to use specialty balloons and devices. The episode also touches on the practical challenges of balancing device cost with treatment effectiveness. The physicians break down the latest specialty balloons and devices and touch on their own experiences with them. To close, the guests share what emerging technologies they're most excited about and how these devices could change their day-to-day practice. Whether you're in IR, cardiology, or vascular surgery, this episode offers a valuable roadmap to the current and future state of vessel preparation. --- TIMESTAMPS 0:00 - Introduction4:07 - New Changes in Techniques14:57 - Vessel Characteristics on Angiogram18:10 - Approaches to Above-the-Knee vs. Below-the-Knee Disease23:48 - Latest Specialty Balloons46:14 - New Devices on the Horizon50:58 - Words of Advice and Final Thoughts --- RESOURCES POINT FORCE Registry: ​​https://evtoday.com/news/cagent-initiates-point-force-registry-of-serranator-pta-catheter?c4src=news

In this episode of Perimenopause: Head to Toe, Dr. Rachel Pope is joined by expert dermatologist Dr. Melissa Mauskar, who dives into how perimenopause and menopause affect our skin. From changes in the face to thinning skin, Dr. Mauskar explains why skin and hair transformations during this time are not only inevitable but also manageable.Dr. Mauskar is an Associate Professor in the Departments of Dermatology and OB-GYN at UT Southwestern Medical Center. She specializes in dermatology, with a focus on vulvar health and dermatologic changes that come with different stages of a woman's life.In this episode, you'll learn: How estrogen, progesterone, and testosterone affect your skin. Why you might notice acne, dryness, or thinning hair in your 40s and beyond. The importance of topical estrogen for maintaining skin thickness. How perimenopause might trigger or worsen conditions like eczema, psoriasis, and even melasma. Tips for preventing skin aging, including the importance of sunscreen and good skincare routines.If you've noticed changes in your skin, this episode offers expert advice on how to address them and what you can do to prevent further damage.About Dr. Mauskar:Dr. Melissa Mauskar is an expert in dermatology and vulvar health, with extensive experience in addressing the skin changes that women experience during perimenopause and menopause. She is the founder of the Vulvar Health Program at UT Southwestern and frequently presents at symposia on women's health dermatology.

An age-friendly approach to arthralgias. Attack arthralgias with ease! Learn how to evaluate and manage common joint complaints in older adults. We're joined by Dr Una Makris, @unamakris.bsky.social (UT Southwestern). Claim CME for this episode at curbsiders.vcuhealth.org! Patreon | Episodes | Subscribe | Spotify | YouTube | Newsletter | Contact | Swag! | CME Show Segments Intro Case 1 from Kashlak General approach to joint pain in older adults Diagnosing osteoarthritis Management of osteoarthritis in older adults Non-pharmacological interventions Pharmacological interventions: topicals, orals, injectables When to refer for joint replacement Case 2 from Kashlak Diagnosis of Late onset rheumatoid arthritis (LORA) Differential Diagnosis and Distinguishing features Lab work/Imaging When to refer to rheumatology Approach to managing LORA The 5Ms framework Initial treatment with glucocorticoids Ageism as a driver of undertreatment in older adults Treating to target Key takeaways  Outro  Credits Producers, Writers and Show Notes: Joseph (Lee) Young, MD, Leah Witt, MD, Rachel Miller, MD Cover Art and Infographic: Leah Witt, MD Hosts: Matthew Watto MD, FACP; Paul Williams MD, FACP    Reviewer: Emi Okamoto, MD Showrunners: Matthew Watto MD, FACP; Paul Williams MD, FACP Technical Production: PodPaste Guest: Dr. Una Makris Disclosures Dr. Makris reports no relevant financial disclosures. The Curbsiders report no relevant financial disclosures. Sponsor: Heart of Care If you care about patient safety, team performance, and building a culture of readiness, subscribe to In the Heart of Care. Available now, wherever you get your podcasts. Sponsor: FIGS Curbsiders listeners can get 15% off. Just go to wearFIGS.com and use code FIGSRX. 

Bob Feldbauer is helping lead two major transformations — one at a national organization, and one at a world-class children's hospital.In this episode, the Healthcare Facilities Network sits down with Bob to talk about the future of the Association of Medical Facility Professionals (AMPF), where he's currently President-Elect. From the organization's growth since 2019 to his goals for 2026 and beyond, Bob offers a forward-looking view of AMPF's evolving role in the industry.We also dive into his work at Children's Health in Dallas, where he's serving as project executive on a $5 billion pediatric campus in collaboration with UT Southwestern, one of the most ambitious healthcare construction projects in the country.If you're interested in where healthcare facilities leadership is headed, this episode is a must-listen.

In this series “evidence today and tomorrow”, the HPB disease site working group of the SSO explored current gaps in HPB surgical oncology, highlighting existing evidence and ongoing work aimed at filling those gaps. In this episode of SurgOnc Today, Dr. Julie Hallet from the Unviersity of Toronto and chair of the SSO HPB Disease Site Working Group, and Dr. Winnie Lo from Eastern Virginia Medical School are joined by Dr. Adam Yopp and Dr. Amit Singal from UT Southwestern, and Dr. Katie Kelley from University of California San Francisco. They will be discussing the state-of-the-art evidence and upcoming trials on treating hepatocellular carcinoma.

Welcome to another episode of the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain, both practicing community oncologists, are joined by Dr. Tian Zhang from UT Southwestern to discuss key highlights from the ASCO 2025 annual meeting, focusing on genitourinary (GU) malignancies. Episode Highlights: • KEYNOTE-564: discussed 5 years OS data, reinforcing the role of adjuvant pembrolizumab in renal cell carcinoma • AMPLITUDE: combination of PARP inhibitor niraparib with abiraterone improved progression-free survival in patients with homologous recombination repair mutations in metastatic hormone-sensitive prostate cancer • ARANOTE: positive quality of life impact when using darolutamide in metastatic hormone-sensitive prostate cancer, which is also FDA approved now • NIAGARA: the prognostic value of ctDNA in muscle-invasive bladder cancer, emphasizing its implications for treatment strategies YouTube: https://youtu.be/Rt8HQpdyVY0 Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Join us as we break down these important studies and their potential to change clinical practice in oncology. Don't forget to check out our other episodes for more insights into cancer care!

Struggling to have your patients show all their skin? Don't worry, we've got just the expert to help. This week, we're joined by Dr. Audrey Rutherford as she dives into the importance of vulvovaginal dermatology. Listen in as she discusses lichen sclerosus, topical steroids, and how to make patients comfortable during full body exams. Each Thursday, join Dr. Raja and Dr. Hadar, board-certified dermatologists, as they share the latest evidence-based research in integrative dermatology. For access to CE/CME courses, become a member at LearnSkin.com. Catch Dr. Rutherford live at IDS2025 for more on vulvovaginal in dermatology! Audrey Rutherford, MD is a board-certified dermatologist specializing in skin cancer, common skin concerns, and complex medical dermatology. She has expertise in dermatologic conditions affecting women's gynecological health, including lichen sclerosus, and is an active member of societies such as ISSVD and ISSWSH, dedicated to these underserved patients. Dr. Rutherford earned her MD from UT Southwestern in Dallas, Texas, where she also completed her rigorous dermatology residency training. She is a Fellow in the American Academy of Dermatology and is a published author contributing to international dermatologic research and education. She is currently practicing and seeing patients in Denver, Colorado.

Podcast: IoT Security Podcast (LS 24 · TOP 10% what is this?)Episode: Real-World Cyber Threats in Healthcare: Balancing Tech, Training, and Human SafetyPub date: 2025-05-27Get Podcast Transcript →powered by Listen411 - fast audio-to-text and summarizationCybersecurity in healthcare is facing heightened challenges as regulations shift, IoT devices proliferate, and ransomware attacks become increasingly devastating. Josh Spencer, Founder, and CIO at FortaTech Security and with over fifteen years in the field including time as CISO/CTO at UT Southwestern, explores why HIPAA changes are necessary, the high stakes of securing medical devices, and how both technology and culture play roles in protecting patient data and safety. The conversation breaks down risks, practical mitigation strategies, and the ongoing evolution of both threats and defensive tools -- including AI --  and covers the evolving HIPAA landscape and the move from “addressable” to required controls, ransomware's impact on hospitals and patient safety, challenges and best practices in securing connected medical (IoT/OT) devices, the importance of real-world risk assessment and penetration testing in healthcare, and human factors, including security awareness training and leveraging AI both for defense and as a threat. Let's connect about IoT Security!Follow John Vecchi at https://www.linkedin.com/in/johnvecchiThe IoT Security Podcast is powered by Phosphorus Cybersecurity. Join the conversation for the IoT Security Podcast — where xIoT meets Security. Learn more at https://phosphorus.io/podcastThe podcast and artwork embedded on this page are from Phosphorus Cybersecurity, which is the property of its owner and not affiliated with or endorsed by Listen Notes, Inc.

Cybersecurity in healthcare is facing heightened challenges as regulations shift, IoT devices proliferate, and ransomware attacks become increasingly devastating. Josh Spencer, Founder, and CIO at FortaTech Security and with over fifteen years in the field including time as CISO/CTO at UT Southwestern, explores why HIPAA changes are necessary, the high stakes of securing medical devices, and how both technology and culture play roles in protecting patient data and safety. The conversation breaks down risks, practical mitigation strategies, and the ongoing evolution of both threats and defensive tools -- including AI --  and covers the evolving HIPAA landscape and the move from “addressable” to required controls, ransomware's impact on hospitals and patient safety, challenges and best practices in securing connected medical (IoT/OT) devices, the importance of real-world risk assessment and penetration testing in healthcare, and human factors, including security awareness training and leveraging AI both for defense and as a threat. Let's connect about IoT Security!Follow Phillip Wylie at https://www.linkedin.com/in/phillipwyliehttps://youtube.com/@phillipwylieThe IoT Security Podcast is powered by Phosphorus Cybersecurity. Join the conversation for the IoT Security Podcast — where xIoT meets Security. Learn more at https://phosphorus.io/podcast

In this episode, Dr. Jaime Almandoz, Associate Professor of Medicine at UT Southwestern, is joined by Dr. Robert F. Kushner, Professor of Medicine at Northwestern University and a leading authority in obesity medicine, to discuss the recent Lancet Diabetes & Endocrinology Commission report, “Definition and Diagnostic Criteria of Clinical Obesity.” The report introduces a new framework for defining clinical and preclinical obesity, aiming to move beyond the limitations of BMI. Dr. Kushner shares insights into the Commission's global consensus process and how the updated definitions can transform care, reduce weight stigma, and support more targeted treatment. Don't miss this timely conversation on the evolving future of obesity diagnosis and management.

Dr. Neil Desai, oncologist at UT Southwestern, provides expert insights on former President Biden’s prostate cancer diagnosis, discussing individualized treatment options and advancements in prostate cancer care.See omnystudio.com/listener for privacy information.

➡️ Join 321,000 people who read my free weekly newsletter: https://newsletter.scottdclary.com➡️ Like The Podcast? Leave A Rating: https://ratethispodcast.com/successstoryDr. Tiffany Moon is a Chinese-American anesthesiologist, entrepreneur, and television personality best known for appearing on The Real Housewives of Dallas. Born in Beijing and raised in the U.S., she earned her medical degree by age 23 and is now an Associate Professor at UT Southwestern. In addition to her medical career, she is the founder of Aromasthesia Candles and Three Moons Wine. A dedicated philanthropist and advocate for AAPI communities, Dr. Moon shares her story of resilience and connection in her upcoming memoir, Joy Prescriptions.➡️ Show Linkshttps://www.instagram.com/tiffanymoonmd/https://www.linkedin.com/in/tiffany-moon-md-fasa-06938455/https://www.tiffanymoonmd.com/ ➡️ Podcast SponsorsHubspot - https://hubspot.com/ Vanta - https://www.vanta.com/scott Federated Computer - https://www.federated.computer Lingoda - https://try.lingoda.com/success_sprintCornbread Hemp - https://cornbreadhemp.com/success (Code: Success)FreshBooks - https://www.freshbooks.com/pricing-offer/ Quince - https://quince.com/success Northwest Registered Agent - https://www.northwestregisteredagent.com/success Prolon - https://prolonlife.com/clary Stash - https://get.stash.com/successstory NetSuite — https://netsuite.com/scottclary/ Indeed - https://indeed.com/clary➡️ Talking Points00:00 – Intro01:34 – The Moment That Changed Everything06:01 – The “Good Asian Daughter” Script08:51 – Breaking Away from Her Parents13:28 – Healing & Finding Joy After Trauma14:39 – Redefining High Performance17:48 – Sponsor Break21:40 – Tiffany's First Taste of Joy30:13 – What Writing Taught Her About Herself32:24 – The #1 Joy-Killing Trait34:30 – Sponsor Break38:35 – Tiffany the Entrepreneur43:15 – Loving the Journey, Not Just the Goal46:57 – Escaping the Scarcity Mindset48:40 – Joy in Her Career53:10 – Comparison: The Thief of Joy1:01:53 – A Lesson for Her KidsSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Listen to ASCO's JCO Oncology Practice, Art of Oncology Practice article, "An Oncologist's Guide to Ensuring Your First Medical Grand Rounds Will Be Your Last” by Dr. David Johnson, who is a clinical oncologist at University of Texas Southwestern Medical School. The article is followed by an interview with Johnson and host Dr. Mikkael Sekeres. Through humor and irony, Johnson critiques how overspecialization and poor presentation practices have eroded what was once internal medicine's premier educational forum. Transcript Narrator: An Oncologist's Guide to Ensuring Your First Medical Grand Rounds Will Be Your Last, by David H. Johnson, MD, MACP, FASCO   Over the past five decades, I have attended hundreds of medical conferences—some insightful and illuminating, others tedious and forgettable. Among these countless gatherings, Medical Grand Rounds (MGRs) has always held a special place. Originally conceived as a forum for discussing complex clinical cases, emerging research, and best practices in patient care, MGRs served as a unifying platform for clinicians across all specialties, along with medical students, residents, and other health care professionals. Expert speakers—whether esteemed faculty or distinguished guests—would discuss challenging cases, using them as a springboard to explore the latest advances in diagnosis and treatment. During my early years as a medical student, resident, and junior faculty member, Grand Rounds consistently attracted large, engaged audiences. However, as medicine became increasingly subspecialized, attendance began to wane. Lectures grew more technically intricate, often straying from broad clinical relevance. The patient-centered discussions that once brought together diverse medical professionals gradually gave way to hyperspecialized presentations. Subspecialists, once eager to share their insights with the wider medical community, increasingly withdrew to their own specialty-specific conferences, further fragmenting the exchange of knowledge across disciplines. As a former Chair of Internal Medicine and a veteran of numerous MGRs, I observed firsthand how these sessions shifted from dynamic educational exchanges to highly specialized, often impenetrable discussions. One of the most striking trends in recent years has been the decline in presentation quality at MGR—even among local and visiting world-renowned experts. While these speakers are often brilliant clinicians and investigators, they can also be remarkably poor lecturers, delivering some of the most uninspiring talks I have encountered. Their presentations are so consistently lackluster that one might suspect an underlying strategy at play—an unspoken method to ensure that they are never invited back. Having observed this pattern repeatedly, I am convinced that these speakers must be adhering to a set of unwritten rules to avoid future MGR presentations. To assist those unfamiliar with this apparent strategy, I have distilled the key principles that, when followed correctly, all but guarantee that a presenter will not be asked to give another MGR lecture—thus sparing them the burden of preparing one in the future. Drawing on my experience as an oncologist, I illustrate these principles using an oncology-based example although I suspect similar rules apply across other subspecialties. It will be up to my colleagues in cardiology, endocrinology, rheumatology, and beyond to identify and document their own versions—tasks for which I claim no expertise. What follows are the seven “Rules for Presenting a Bad Medical Oncology Medical Grand Rounds.” 1.  Microscopic Mayhem: Always begin with an excruciatingly detailed breakdown of the tumor's histology and molecular markers, emphasizing how these have evolved over the years (eg, PAP v prostate-specific antigen)—except, of course, when they have not (eg, estrogen receptor, progesterone receptor, etc). These nuances, while of limited relevance to general internists or most subspecialists (aside from oncologists), are guaranteed to induce eye-glazing boredom and quiet despair among your audience. 2. TNM Torture: Next, cover every nuance of the newest staging system … this is always a real crowd pleaser. For illustrative purposes, show a TNM chart in the smallest possible font. It is particularly helpful if you provide a lengthy review of previous versions of the staging system and painstakingly cover each and every change in the system. Importantly, this activity will allow you to disavow the relevance of all previous literature studies to which you will subsequently refer during the course of your presentation … to wit—“these data are based on the OLD staging system and therefore may not pertain …” This phrase is pure gold—use it often if you can. NB: You will know you have “captured” your audience if you observe audience members “shifting in their seats” … it occurs almost every time … but if you have failed to “move” the audience … by all means, continue reading … there is more! 3. Mechanism of Action Meltdown: Discuss in detail every drug ever used to treat the cancer under discussion; this works best if you also give a detailed description of each drug's mechanism of action (MOA). General internists and subspecialists just LOVE hearing a detailed discussion of the drug's MOA … especially if it is not at all relevant to the objectives of your talk. At this point, if you observe a wave of slack-jawed faces slowly slumping toward their desktops, you will know you are on your way to successfully crushing your audience's collective spirit. Keep going—you are almost there. 4. Dosage Deadlock: One must discuss “dose response” … there is absolutely nothing like a dose response presentation to a group of internists to induce cries of anguish. A wonderful example of how one might weave this into a lecture to generalists or a mixed audience of subspecialists is to discuss details that ONLY an oncologist would care about—such as the need to dose escalate imatinib in GIST patients with exon 9 mutations as compared with those with exon 11 mutations. This is a definite winner! 5. Criteria Catatonia: Do not forget to discuss the newest computed tomography or positron emission tomography criteria for determining response … especially if you plan to discuss an obscure malignancy that even oncologists rarely encounter (eg, esthesioneuroblastoma). Should you plan to discuss a common disease you can ensure ennui only if you will spend extra time discussing RECIST criteria. Now if you do this well, some audience members may begin fashioning their breakfast burritos into projectiles—each one aimed squarely at YOU. Be brave … soldier on! 6. Kaplan-Meier Killer: Make sure to discuss the arcane details of multiple negative phase II and III trials pertaining to the cancer under discussion. It is best to show several inconsequential and hard-to-read Kaplan-Meier plots. To make sure that you do a bad job, divide this portion of your presentation into two sections … one focused on adjuvant treatment; the second part should consist of a long boring soliloquy on the management of metastatic disease. Provide detailed information of little interest even to the most ardent fan of the disease you are discussing. This alone will almost certainly ensure that you will never, ever be asked to give Medicine Grand Rounds again. 7. Lymph Node Lobotomy: For the coup de grâce, be sure to include an exhaustive discussion of the latest surgical techniques, down to the precise number of lymph nodes required for an “adequate dissection.” To be fair, such details can be invaluable in specialized settings like a tumor board, where they send subspecialists into rapturous delight. But in the context of MGR—where the audience spans multiple disciplines—it will almost certainly induce a stultifying torpor. If dullness were an art, this would be its masterpiece—capable of lulling even the most caffeinated minds into a stupor. If you have carefully followed the above set of rules, at this point, some members of the audience should be banging their heads against the nearest hard surface. If you then hear a loud THUD … and you're still standing … you will know you have succeeded in giving the world's worst Medical Grand Rounds!   Final Thoughts I hope that these rules shed light on what makes for a truly dreadful oncology MGR presentation—which, by inverse reasoning, might just serve as a blueprint for an excellent one. At its best, an outstanding lecture defies expectations. One of the most memorable MGRs I have attended, for instance, was on prostaglandin function—not a subject typically associated with edge-of-your-seat suspense. Given by a biochemist and physician from another subspecialty, it could have easily devolved into a labyrinth of enzymatic pathways and chemical structures. Instead, the speaker took a different approach: rather than focusing on biochemical minutiae, he illustrated how prostaglandins influence nearly every major physiologic system—modulating inflammation, regulating cardiovascular function, protecting the gut, aiding reproduction, supporting renal function, and even influencing the nervous system—without a single slide depicting the prostaglandin structure. The result? A room full of clinicians—not biochemists—walked away with a far richer understanding of how prostaglandins affect their daily practice. What is even more remarkable is that the talk's clarity did not just inform—it sparked new collaborations that shaped years of NIH-funded research. Now that was an MGR masterpiece. At its core, effective scientific communication boils down to three deceptively simple principles: understanding your audience, focusing on relevance, and making complex information accessible.2 The best MGRs do not drown the audience in details, but rather illuminate why those details matter. A great lecture is not about showing how much you know, but about ensuring your audience leaves knowing something they didn't before. For those who prefer the structured wisdom of a written guide over the ramblings of a curmudgeon, an excellent review of these principles—complete with a handy checklist—is available.2 But fair warning: if you follow these principles, you may find yourself invited back to present another stellar MGRs. Perish the thought! Dr. Mikkael SekeresHello and welcome to JCO's Cancer Stories: The Art of Oncology, which features essays and personal reflections from authors exploring their experience in the oncology field. I'm your host, Mikkael Sekeres. I'm Professor of Medicine and Chief of the Division of Hematology at the Sylvester Comprehensive Cancer Center, University of Miami.  What a pleasure it is today to be joined by Dr. David Johnson, clinical oncologist at the University of Texas Southwestern Medical School. In this episode, we will be discussing his Art of Oncology Practice article, "An Oncologist's Guide to Ensuring Your First Medical Grand Rounds Will Be Your Last."  Our guest's disclosures will be linked in the transcript.  David, welcome to our podcast and thanks so much for joining us. Dr. David JohnsonGreat to be here, Mikkael. Thanks for inviting me. Dr. Mikkael SekeresI was wondering if we could start with just- give us a sense about you. Can you tell us about yourself? Where are you from? And walk us through your career. Dr. David JohnsonSure. I grew up in a small rural community in Northwest Georgia about 30 miles south of Chattanooga, Tennessee, in the Appalachian Mountains. I met my wife in kindergarten. Dr. Mikkael SekeresOh my. Dr. David JohnsonThere are laws in Georgia. We didn't get married till the third grade. But we dated in high school and got married after college. And so we've literally been with one another my entire life, our entire lives. Dr. Mikkael SekeresMy word. Dr. David JohnsonI went to medical school in Georgia. I did my training in multiple sites, including my oncology training at Vanderbilt, where I completed my training. I spent the next 30 years there, where I had a wonderful career. Got an opportunity to be a Division Chief and a Deputy Director of, and the founder of, a cancer center there. And in 2010, I was recruited to UT Southwestern as the Chairman of Medicine. Not a position I had particularly aspired to, but I was interested in taking on that challenge, and it proved to be quite a challenge for me. I had to relearn internal medicine, and really all the subspecialties of medicine really became quite challenging to me. So my career has spanned sort of the entire spectrum, I suppose, as a clinical investigator, as an administrator, and now as a near end-of-my-career guy who writes ridiculous articles about grand rounds. Dr. Mikkael SekeresNot ridiculous at all. It was terrific. What was that like, having to retool? And this is a theme you cover a little bit in your essay, also, from something that's super specialized. I mean, you have had this storied career with the focus on lung cancer, and then having to expand not only to all of hematology oncology, but all of medicine. Dr. David JohnsonIt was a challenge, but it was also incredibly fun. My first few days in the chair's office, I met with a number of individuals, but perhaps the most important individuals I met with were the incoming chief residents who were, and are, brilliant men and women. And we made a pact. I promised to teach them as much as I could about oncology if they would teach me as much as they could about internal medicine. And so I spent that first year literally trying to relearn medicine. And I had great teachers. Several of those chiefs are now on the faculty here or elsewhere. And that continued on for the next several years. Every group of chief residents imparted their wisdom to me, and I gave them what little bit I could provide back to them in the oncology world. It was a lot of fun. And I have to say, I don't necessarily recommend everybody go into administration. It's not necessarily the most fun thing in the world to do. But the opportunity to deal one-on-one closely with really brilliant men and women like the chief residents was probably the highlight of my time as Chair of Medicine. Dr. Mikkael SekeresThat sounds incredible. I can imagine, just reflecting over the two decades that I've been in hematology oncology and thinking about the changes in how we diagnose and care for people over that time period, I can only imagine what the changes had been in internal medicine since I was last immersed in that, which would be my residency. Dr. David JohnsonWell, I trained in the 70s in internal medicine, and what transpired in the 70s was kind of ‘monkey see, monkey do'. We didn't really have a lot of understanding of pathophysiology except at the most basic level. Things have changed enormously, as you well know, certainly in the field of oncology and hematology, but in all the other fields as well. And so I came in with what I thought was a pretty good foundation of knowledge, and I realized it was completely worthless, what I had learned as an intern and resident. And when I say I had to relearn medicine, I mean, I had to relearn medicine. It was like being an intern. Actually, it was like being a medical student all over again. Dr. Mikkael SekeresOh, wow. Dr. David JohnsonSo it's quite challenging.  Dr. Mikkael SekeresWell, and it's just so interesting. You're so deliberate in your writing and thinking through something like grand rounds. It's not a surprise, David, that you were also deliberate in how you were going to approach relearning medicine. So I wonder if we could pivot to talking about grand rounds, because part of being a Chair of Medicine, of course, is having Department of Medicine grand rounds. And whether those are in a cancer center or a department of medicine, it's an honor to be invited to give a grand rounds talk. How do you think grand rounds have changed over the past few decades? Can you give an example of what grand rounds looked like in the 1990s compared to what they look like now? Dr. David JohnsonWell, I should all go back to the 70s and and talk about grand rounds in the 70s. And I referenced an article in my essay written by Dr. Ingelfinger, who many people remember Dr. Ingelfinger as the Ingelfinger Rule, which the New England Journal used to apply. You couldn't publish in the New England Journal if you had published or publicly presented your data prior to its presentation in the New England Journal. Anyway, Dr. Ingelfinger wrote an article which, as I say, I referenced in my essay, about the graying of grand rounds, when he talked about what grand rounds used to be like. It was a very almost sacred event where patients were presented, and then experts in the field would discuss the case and impart to the audience their wisdom and knowledge garnered over years of caring for patients with that particular problem, might- a disease like AML, or lung cancer, or adrenal insufficiency, and talk about it not just from a pathophysiologic standpoint, but from a clinician standpoint. How do these patients present? What do you do? How do you go about diagnosing and what can you do to take care of those kinds of patients? It was very patient-centric. And often times the patient, him or herself, was presented at the grand rounds. And then experts sitting in the front row would often query the speaker and put him or her under a lot of stress to answer very specific questions about the case or about the disease itself.  Over time, that evolved, and some would say devolved, but evolved into more specialized and nuanced presentations, generally without a patient present, or maybe even not even referred to, but very specifically about the molecular biology of disease, which is marvelous and wonderful to talk about, but not necessarily in a grand round setting where you've got cardiologists sitting next to endocrinologists, seated next to nephrologists, seated next to primary care physicians and, you know, an MS1 and an MS2 and et cetera. So it was very evident to me that what I had witnessed in my early years in medicine had really become more and more subspecialized. As a result, grand rounds, which used to be packed and standing room only, became echo chambers. It was like a C-SPAN presentation, you know, where local representative got up and gave a talk and the chambers were completely empty. And so we had to go to do things like force people to attend grand rounds like a Soviet Union-style rally or something, you know. You have to pay them to go. But it was really that observation that got me to thinking about it.  And by the way, I love oncology and I'm, I think there's so much exciting progress that's being made that I want the presentations to be exciting to everybody, not just to the oncologist or the hematologist, for example. And what I was witnessing was kind of a formula that, almost like a pancake formula, that everybody followed the same rules. You know, “This disease is the third most common cancer and it presents in this way and that way.” And it was very, very formulaic. It wasn't energizing and exciting as it had been when we were discussing individual patients. So, you know, it just is what it is. I mean, progress is progress and you can't stop it. And I'm not trying to make America great again, you know, by going back to the 70s, but I do think sometimes we overthink what medical grand rounds ought to be as compared to a presentation at ASH or ASCO where you're talking to subspecialists who understand the nuances and you don't have to explain the abbreviations, you know, that type of thing. Dr. Mikkael SekeresSo I wonder, you talk about the echo chamber of the grand rounds nowadays, right? It's not as well attended. It used to be a packed event, and it used to be almost a who's who of, of who's in the department. You'd see some very famous people who would attend every grand rounds and some up-and-comers, and it was a chance for the chief residents to shine as well. How do you think COVID and the use of Zoom has changed the personality and energy of grand rounds? Is it better because, frankly, more people attend—they just attend virtually. Last time I attended, I mean, I attend our Department of Medicine grand rounds weekly, and I'll often see 150, 200 people on the Zoom. Or is it worse because the interaction's limited? Dr. David JohnsonYeah, I don't want to be one of those old curmudgeons that says, you know, the way it used to be is always better. But there's no question that the convenience of Zoom or similar media, virtual events, is remarkable. I do like being able to sit in my office where I am right now and watch a conference across campus that I don't have to walk 30 minutes to get to. I like that, although I need the exercise. But at the same time, I think one of the most important aspects of coming together is lost with virtual meetings, and that's the casual conversation that takes place. I mentioned in my essay an example of the grand rounds that I attended given by someone in a different specialty who was both a physician and a PhD in biochemistry, and he was talking about prostaglandin metabolism. And talk about a yawner of a title; you almost have to prop your eyelids open with toothpicks. But it turned out to be one of the most fascinating, engaging conversations I've ever encountered. And moreover, it completely opened my eyes to an area of research that I had not been exposed to at all. And it became immediately obvious to me that it was relevant to the area of my interest, which was lung cancer. This individual happened to be just studying colon cancer. He's not an oncologist, but he was studying colon cancer. But it was really interesting what he was talking about. And he made it very relevant to every subspecialist and generalist in the audience because he talked about how prostaglandin has made a difference in various aspects of human physiology.  The other grand rounds which always sticks in my mind was presented by a long standing program director at my former institution of Vanderbilt. He's passed away many years ago, but he gave a fascinating grand rounds where he presented the case of a homeless person. I can't remember the title of his grand rounds exactly, but I think it was “Care of the Homeless” or something like that. So again, not something that necessarily had people rushing to the audience. What he did is he presented this case as a mysterious case, you know, “what is it?” And he slowly built up the presentation of this individual who repeatedly came to the emergency department for various and sundry complaints. And to make a long story short, he presented a case that turned out to be lead poisoning. Everybody was on the edge of their seat trying to figure out what it was. And he was challenging members of the audience and senior members of the audience, including the Cair, and saying, “What do you think?” And it turned out that the patient became intoxicated not by eating paint chips or drinking lead infused liquids. He was burning car batteries to stay alive and inhaling lead fumes, which itself was fascinating, you know, so it was a fabulous grand rounds. And I mean, everybody learned something about the disease that they might otherwise have ignored, you know, if it'd been a title “Lead Poisoning”, I'm not sure a lot of people would have shown up. Dr. Mikkael Sekeres That story, David, reminds me of Tracy Kidder, who's a master of the nonfiction narrative, will choose a subject and kind of just go into great depth about it, and that subject could be a person. And he wrote a book called Rough Sleepers about Jim O'Connell - and Jim O'Connell was one of my attendings when I did my residency at Mass General - and about his life and what he learned about the homeless. And it's this same kind of engaging, “Wow, I never thought about that.” And it takes you in a different direction.  And you know, in your essay, you make a really interesting comment. You reflect that subspecialists, once eager to share their insight with the wider medical community, increasingly withdraw to their own specialty specific conferences, further fragmenting the exchange of knowledge across disciplines. How do you think this affects their ability to gain new insights into their research when they hear from a broader audience and get questions that they usually don't face, as opposed to being sucked into the groupthink of other subspecialists who are similarly isolated? Dr. David Johnson That's one of the reasons I chose to illustrate that prostaglandin presentation, because again, that was not something that I specifically knew much about. And as I said, I went to the grand rounds more out of a sense of obligation than a sense of engagement. Moreover, our Chair at that institution forced us to go, so I was there, not by choice, but I'm so glad I was, because like you say, I got insight into an area that I had not really thought about and that cross pollination and fertilization is really a critical aspect. I think that you can gain at a broad conference like Medical Grand Rounds as opposed to a niche conference where you're talking about APL. You know, everybody's an APL expert, but they never thought about diabetes and how that might impact on their research. So it's not like there's an ‘aha' moment at every Grand Rounds, but I do think that those kinds of broad based audiences can sometimes bring a different perspective that even the speaker, him or herself had not thought of. Dr. Mikkael SekeresI think that's a great place to end and to thank David Johnson, who's a clinical oncologist at the University of Texas Southwestern Medical School and just penned the essay in JCO Art of Oncology Practice entitled "An Oncologist's Guide to Ensuring Your First Medical Grand Rounds Will Be Your Last."  Until next time, thank you for listening to JCO's Cancer Stories: The Art of Oncology. Don't forget to give us a rating or review, and be sure to subscribe so you never miss an episode. You can find all of ASCO's shows at asco.org/podcasts.  David, once again, I want to thank you for joining me today. Dr. David JohnsonThank you very much for having me. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.    Show notes: Like, share and subscribe so you never miss an episode and leave a rating or review.  Guest Bio: Dr David Johnson is a clinical oncologist at the University of Texas Southwestern Medical School.

Are you feeling the weight of perfectionism and the constant need to achieve? Dr. Tiffany Moon's journey is a testament to how the pressure to be perfect can hinder personal fulfillment. As a successful physician, reality TV star, and author, she realized that her life was driven by external accomplishments rather than internal joy.  In this episode, Dr. Tiffany shares how she stopped living for external validation and began to align her actions with her authentic self. From moving away from toxic friendships to learning the art of saying no, she highlights the importance of setting boundaries and prioritizing well-being over societal expectations.  Her book, Joy Prescriptions, explores this journey and how Dr. Tiffany applied her doctor's mindset to prescribe joy in everyday life. It's not just about removing the negative but creating space for what truly brings happiness.  Ready to start your own journey of self-rediscovery? Join us as we explore how you can overcome perfectionism, prioritize joy, and live a life that feels as good on the inside as it looks on the outside.  "To stop filling your bucket with the wrong things is a mindset shift. First, you change your mindset, and then you start doing things that fall in line with the new mindset." ~ Dr. Tiffany Moon In this Episode: - Meet Dr. Tiffany Moon - Behind the scenes of the Real Housewives of Dallas - Jen's Real Housewives experience - Dr. Tiffany's upbringing, academic achievements, and career - Escaping the trap of perfectionism and reconstructing Life - Finding healing: therapy, self-help books, and a "friends" audit - Tiffany's Real Housewives experience  - Dr. Tiffany's life and career after her awakening - How to pre-order the Joy Prescriptions book  About Dr. Tiffany Moon: Dr. Tiffany Moon is a board-certified anesthesiologist, entrepreneur, and author. She is a proud mother of twins and a dynamic television and social media personality. Dr. Tiffany graduated from Cornell University at 19, earned her medical degree with Alpha Omega Alpha Honors from UT Southwestern, and completed her anesthesiology residency at UCSF. She has been named one of D Magazine's Best Doctors, authored over 50 peer-reviewed publications, been recognized as a Distinguished Educator by the American Society of Anesthesiologists, and serves as an Oral Board Examiner for the American Board of Anesthesiology. She is the founder and CEO of Aromasthesia Candle Company, Three Moons Wine, and LeadHer Summit. Her debut book, Joy Prescriptions—a powerful exploration of overcoming perfectionism and finding joy through gratitude, self-compassion, and connection—will be published in May 2025. Pre-order Joy Prescriptions: https://www.joyprescriptions.com/  Website: https://www.tiffanymoonmd.com/  Instagram: https://www.instagram.com/tiffanymoonmd/  Facebook: https://www.facebook.com/tiffanymoonmd  Where to find me: IG: https://www.instagram.com/jen_gottlieb/    TikTok: https://www.tiktok.com/@jen_gottlieb     Facebook: https://www.facebook.com/Jenleahgottlieb    Website: https://jengottlieb.com/    My business: https://www.superconnectormedia.com/     YouTube: https://www.youtube.com/@jen_gottlieb

In this episode, Dr. Seema Khosla talks with women's sleep expert Dr. Safia Khan about women's unique sleep challenges. Dr. Khan is an editor for "A Clinical Casebook of Sleep Disorders in Women" and specializes in women's sleep health at UT Southwestern. She explains how sleep disorders affect women differently across their lives, particularly during pregnancy and menopause, and how these transitions disrupt normal sleep patterns.  Discover Dr. Khan's assessment strategies for insomnia in women, including decision-making frameworks for implementing CBT-I versus medication interventions. Learn about the underdiagnosis of sleep disorders in women, particularly during menopause, and strategies for changing this normalized narrative. The conversation explores the physiological differences in sleep-disordered breathing between men and women, explaining why sleep apnea incidence equalizes during menopause.  The discussion addresses managing hypersomnia during pregnancy, approaches to fatigue without diagnosed sleep disorders, connections between PCOS and sleep disruption, and guidance on Restless Legs Syndrome management, including the critical role of iron deficiency screening in adolescent girls.  This episode provides essential knowledge for practitioners seeking to better understand and treat the unique sleep health challenges women face across their lifespans. 

Dr. Sandra Hassink is joined by Dr. Sarah Barlow, a professor of pediatrics at UT Southwestern in Dallas and head of the children's hospital integrated programs on obesity. Together, they discuss the new Healthy Eating Research consensus recommendations on healthy beverage consumption. Resources: • Healthy Beverage Consumption in School-Age Children and Adolescents: Recommendations from Key National Health and Nutrition Organizations (https://tinyurl.com/2hztabmd) • Healthy Beverage Consumption in Early Childhood (https://tinyurl.com/3fjp39v6) • Healthy Beverage Quick Reference Guide (https://tinyurl.com/5n8tcte6)

The mother of a 5-year-old boy found dead in South Dallas was sentenced to life in prison last week for beating the child. 29 year old Tiffany Williams was found guilty Friday of injury to a child in connection with the 2022 death of Zamaurian Kizzee. The boy's legal father, 77 year old Ulysses Kizzee, faces a charge of injury to a child by omission. In other news, Southwestern Health Resources, which includes the medical providers and hospitals at Texas Health Resources and UT Southwestern are no longer in-network for Blue Cross and Blue Shield of Texas insurance plans, including commercial plans, as well as Medicaid and Medicare Advantage plans; Big Bend National Park in Texas could soon expand by thousands of acres. Three lawmakers — U.S. Sens. John Cornyn, R-Texas, and Ben Ray Luján D-New Mexico, and U.S. Rep. Tony Gonzales, R-San Antonio — introduced a bill in Congress last month to acquire roughly 6,100 acres along the park's western boundary; and April is Dallas Arts Month and the city is buzzing with fresh, interactive ways to experience art and music. Check out the trends taking over the city in today's edition of the Dallas Morning News. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Welcome to another episode of the Oncology Brothers! In this episode, Drs. Rahul and Rohit Gosain are joined by their brother, Dr. Timothy Brown from UT Southwestern, to discuss the latest treatment paradigms for upper gastrointestinal (GI) malignancies, specifically focusing on esophageal and gastroesophageal junction adenocarcinoma, as well as gastric cancer. Episode Highlights: •⁠  ⁠Early Disease Management: perioperative FLOT versus concurrent chemoradiation. •⁠  ⁠Adjuvant Nivolumab: Insights from the Checkmate 577 trial and its implications for patients with residual disease post-chemoradiation. •⁠  ⁠Biomarker Testing: The importance of testing for MSI, HER2, Claudin 18.2, and PD-L1 to guide treatment decisions in metastatic settings. •⁠  ⁠Patient-Centered Care: Emphasizing the significance of shared decision-making and multidisciplinary approaches in managing complex cases. Join us as we unpack the nuances of upper GI malignancies and share key takeaways from recent studies and clinical practices.  YouTube: https://youtu.be/UNyi71u2wIw Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more updates on treatment algorithms and oncology insights!  

It is Triple Negative Breast Cancer Day – an annual opportunity to bring more awareness to this aggressive type of breast cancer that is difficult to treat because it lacks an estrogen, progesterone and HER2 receptor. It primarily affects younger women and Black women and can spread quickly and be deadly if left untreated for too long. Treatment for TNBC used to include the toughest forms of chemotherapy, with debilitating side effects – but we've come a long way in how we treat patients with Triple Negative Breast Cancer so their outcomes are better. Today, we are speaking with Dr. Heather McArthur of UT Southwestern. She is a former Susan G. Komen grantee, Professor and the Komen Distinguished Chair in Clinical Breast Cancer Research. Dr. McArthur has been working on a Phase 3 clinical trial called KEYNOTE-522, which is testing whether a specific immunotherapy drug improves overall survival for people with high-risk early Triple Negative Breast Cancer. Dr. McArthur, along with her colleagues, are trying to determine if all people with this type of breast cancer truly need the drug, and if not, who would most benefit from taking it.

Dr. Joseph S. Takahashi is Professor and Chair of Neuroscience and the Loyd B. Sands Distinguished Chair in Neuroscience at the University of Texas Southwestern Medical Center. He is also an Investigator in the Howard Hughes Medical Institute. Joe and his lab members are trying to better understand the biological clocks in our bodies that control our 24-hour schedules. Within each of us are internal clocks that are genetically controlled. A special set of genes within nearly all of our cells turns on and off each day to regulate a wide variety of biological functions, and Joe is studying these genes and how they contribute to our biological rhythms. Functions influenced by our biological clocks include our sleep schedules, blood sugar, body temperature, liver metabolism, and many other aspects of our physiology. When Joe isn't at work, he enjoys playing tennis, skiing, hiking, eating delicious food, and drinking great wine. Joe received his B.A. in biology from Swarthmore College and he was awarded his Ph.D. in neuroscience from the University of Oregon in Eugene. Afterwards, he conducted postdoctoral research as a pharmacology research associate at the National Institute of Mental Health. Before moving to UT Southwestern, Joe served on the faculty of Northwestern University for 26 years. Over the course of his career, Joe has received numerous awards and honors including the Honma Prize in Biological Rhythms Research, the NSF Presidential Young Investigator Award, the Searle Scholars Award, the Bristol-Myers Squibb Unrestricted Grant in Neuroscience, the C. U. Ariens Kappers Medal, the Outstanding Scientific Achievement Award from the Sleep Research Society, the W. Alden Spencer Award in Neuroscience from Columbia University, and the Peter C. Farrell Prize in Sleep Medicine from the Harvard Medical School Division of Sleep Medicine. He has also been elected as a Fellow of the American Academy of Arts and Sciences, a Fellow of the American Association for the Advancement of Science, a Member of the National Academy of Sciences, a Member of the National Academy of Medicine, and an Honorary Member of The Japanese Biochemical Society. In our interview, Joe shared his experiences in life and science.

This week, we are joined by Anila D'Mello, an assistant professor at UT Southwestern, whose groundbreaking research uses neuroimaging to explore the brain circuits that support language and cognition in autism. Dr. D'Mello will share insights from her work on cerebro-cerebellar circuits and how they differ in neurodevelopmental disorders. Join us as we discuss how these findings can transform our understanding of autism and inform future interventions. Download episode to learn more! Resources  A seat at the (language) table: incorporating the cerebellum into frameworks for language processingLeBel, A., D'Mello, A.M Current Opinion in Behavioral Sciences 2024   Exclusion of females in autism research: Empirical evidence for a "leaky" recruitment-to-research pipeline.D'Mello AM, Frosch IR, Li CE, Cardinaux AL, Gabrieli JDE, Autism Res 2022 Aug   Cerebellar Contributions to Social Cognition in ASD: A Predictive Processing Framework.Frosch IR, Mittal VA, D'Mello AM, Front Integr Neurosci 2022 16 810425   Enhanced rationality in autism spectrum disorder.Rozenkrantz L, D'Mello AM, Gabrieli JDE, Trends Cogn Sci 2021 08 25 8 685-696   Differential Behavioral and Neural Effects of Regional Cerebellar tDCS.Rice LC, D'Mello AM, Stoodley CJ, Neuroscience 2021 05 462 288-302   Anxiety, Motivation, and Competence in Mathematics and Reading for Children With and Without Learning Difficulties.Pollack C, Wilmot D, Centanni TM, Halverson K, Frosch I, D'Mello AM, Romeo RR, Imhof A, Capella J, Wade K, Al Dahhan NZ, Gabrieli JDE, Christodoulou JA, Front Psychol 2021 12 704821 ............................................................... Autism weekly is now found on all of the major listening apps including apple podcasts, google podcasts, stitcher, Spotify, amazon music, and more. Subscribe to be notified when we post a new podcast. Autism weekly is produced by ABS Kids. ABS Kids is proud to provide diagnostic assessments and ABA therapy to children with developmental delays like Autism Spectrum Disorder. You can learn more about ABS Kids and the Autism Weekly podcast by visiting abskids.com.

It will be mostly cloudy today with rain and a possible thunderstorm in the area. The high will be 73. The rain will linger into the evening, otherwise cloudy with a low of 56. The Dallas Cowboys beat the Carolina Panthers 30-14 yesterday and kept their slim playoff hopes alive. It's still hard to fathom a scenario that has the Cowboys making the playoffs, but they're not done yet; In other news, Win a marathon on your first time running the distance? That's exactly what Travis Dowd did Sunday morning at the 2024 BMW Dallas Marathon. The current UT Southwestern medical student and Rice alumnus broke the tape in a time of 2:26:08, winning by over four minutes over the rest of the competition; Shannah and Kelly Hayley didn't run their first races until their 30s. And now the Plano couple have completed their goal of running marathons and half marathons in all 50 states before their 55th birthdays. Shannah and Kelly lead a run club and started working toward their 50-state goal around five years ago; And, in a study conducted by The Action Network, Texas has been identified as the state with the highest risk of porch piracy, with a 29.8% probability of package theft. Learn more about your ad choices. Visit podcastchoices.com/adchoices

In this episode of SurgOnc Today®, Dr. Julie Hallet, Chair of the HPB Disease Site Work Group, and Dr. Patricio Polanco, Vice-Chair of the HPB Disease Site Work Group, are joined by Drs. Sajid Khan from Yale School of Medicine and Dr. Cecilia Ethun from UT Southwestern. They will wrap the 2024 HPB year by reviewing the top HPB surgical oncology published this year.  References/Resources: #10: AMPLIFY https://www.nature.com/articles/s41591-023-02760-3   #9: Adjuvant therapy for IPMN-derived PDAC - https://ascopubs.org/doi/abs/10.1200/JCO.23.02313   #8: HELIX https://jamanetwork.com/journals/jama/fullarticle/2822555  #7: CAMINO  https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00572-7/fulltext  #5 : PANDAS/PRODIGE https://www.annalsofoncology.org/article/S0923-7534(24)03884-5/fulltext

David explains, "We went to the Simons Foundation and, with their support, have established a network in the United States. We have three collection sites: one at the UC Davis Mind Institute in Sacramento, one at UT Southwestern in Dallas, Texas, and one at the Mass General Hospital in Boston, where a postmortem brain donation can be sent. Those brains are then prepared in ways that will facilitate all kinds of research both now and in the future. We have developed this resource to foster autism research throughout the world. What we are seeing now that we've just celebrated our 10th anniversary is that we've collected nearly 400 brain donations so far, and we're seeing an increasing demand from researchers worldwide to get access to that resource." Dorothy elaborates, "I was the main support person for my older cousin, Gregory Blackstock, for a couple of decades. He needed a lot of executive function help. He lived on his own but couldn't make critical decisions very well. As long as everything went along without any hitch, he was generally fine. But as he got older and experienced more physical infirmities, then I needed to step up more. So then he was very obviously autistic, so it was kind of peripherally interesting to me." "One of his savant traits was that he was an incredible artist. He also spoke many languages that he picked up by ear. He had a perfect pitch and learned the accordion, but he could easily transfer that information to playing the organ and the piano. He had almost total recall of anything that crossed his path that interested him. And so, just being around him and being involved with furthering his artistic career gave me further insights about the people I met who were interested in autism."   #AutismBrainNet #BrainDonation #AutismResearch #Autism #BrainResearch autismbrainnet.org Listen to the podcast here

This is a conversation with Dr. David Amaral, a distinguished professor at the MIND Institute and scientific director of Autism BrainNet, and Dorothy Frisch, an activist and supporter of the program. Autism BrainNet is funded by the Simons Foundation to collect and study postmortem brain samples from individuals with autism to understand the neurological basis of the disorder better. Currently, there are no biomarkers for autism, so studying the brains and accomplishments of those who had autism can lead to a better understanding of the abilities and challenges seen on the autism spectrum. David explains, "We went to the Simons Foundation and, with their support, have established a network in the United States. We have three collection sites: one at the UC Davis Mind Institute in Sacramento, one at UT Southwestern in Dallas, Texas, and one at the Mass General Hospital in Boston, where a postmortem brain donation can be sent. Those brains are then prepared in ways that will facilitate all kinds of research both now and in the future. We have developed this resource to foster autism research throughout the world. What we are seeing now that we've just celebrated our 10th anniversary is that we've collected nearly 400 brain donations so far, and we're seeing an increasing demand from researchers worldwide to get access to that resource." Dorothy elaborates, "I was the main support person for my older cousin, Gregory Blackstock, for a couple of decades. He needed a lot of executive function help. He lived on his own but couldn't make critical decisions very well. As long as everything went along without any hitch, he was generally fine. But as he got older and experienced more physical infirmities, then I needed to step up more. So then he was very obviously autistic, so it was kind of peripherally interesting to me." "One of his savant traits was that he was an incredible artist. He also spoke many languages that he picked up by ear. He had a perfect pitch and learned the accordion, but he could easily transfer that information to playing the organ and the piano. He had almost total recall of anything that crossed his path that interested him. And so, just being around him and being involved with furthering his artistic career gave me further insights about the people I met who were interested in autism."   #AutismBrainNet #BrainDonation #AutismResearch #Autism #BrainResearch autismbrainnet.org Download the transcript here  

Welcome to another episode of the Oncology Brothers! In this episode, hosts Drs. Rahul and Rohit Gosain dive into the complexities of managing side effects associated with antibody drug conjugates (ADCs). Joined by expert guests Dr. Tian Zhang, a GU medical oncologist from UT Southwestern, and Dr. Erika Hamilton from Sarah Cannon Research Institute, the discussion focuses on three key ADCs: Enfortumab vedotin, Sacituzumab govitecan, and Trastuzumab deruxtecan (TDXD). Episode Highlights: •⁠  ⁠Enfortumab vedotin: Learn about the common side effects such as skin toxicities, hyperglycemia, and neuropathy, and how to manage them effectively in clinical practice. •⁠  ⁠Sacituzumab govitecan: Explore the challenges of neutropenia, diarrhea, and fatigue, and the importance of individualized patient care. •⁠  ⁠Trastuzumab deruxtecan (TDXD): Understand the critical side effects including nausea, fatigue, and interstitial lung disease (ILD), and the strategies for prevention and management. This episode emphasizes the importance of recognizing and acting on side effects that can significantly impact patient outcomes. Whether you're a healthcare professional or someone interested in oncology, this discussion will provide valuable insights into toxicity management for ADCs. Don't forget to like, subscribe, and check out more episodes for in-depth discussions on oncology topics! Website: http://www.oncbrothers.com/ X/Twitter: https://twitter.com/oncbrothers Contact us at info@oncbrothers.com

In this episode, Scott Becker discusses healthcare workforce strategies, highlighting HCA Midwest's partnership with Avila University and Cottage Hospital's initiatives to "grow their own" staff. He also explores significant facility investments by UT Southwestern and Mass General Brigham, updates on healthcare stock performance, and insights into GLP-1 drugs and Medicare/Medicaid coverage proposals.

Leaders from the top-polluting countries, like the US and China, aren't showing up to the UN's big climate conference in Azerbaijan. And, walking pneumonia typically affects school-age kids, but the CDC reports a rise in cases in children aged 2-4.At COP29, The World's Top Polluters Are No-ShowsThe United Nations' annual international climate conference, COP29, got underway this week in Baku, Azerbaijan. Leaders from around the world come together at this conference to hammer out deals between nations to lower emissions and coordinate climate change-related financial efforts.And a big focus this year was to negotiate a deal for wealthier countries to financially compensate developing nations who've experienced climate-change related damage. The only problem is that world leaders from the top-polluting countries, like the US and China, aren't even showing up.Ira Flatow is joined by Umair Irfan, senior correspondent at Vox, to catch up on this and other science stories of the week, including new data on rising alcohol consumption, why Voyager 2 got an inaccurate snapshot of Uranus in the 1980s, and why the world's largest organism might also be its oldest.Walking Pneumonia Is Spiking. Here's How To Stay SafeLast month, the Centers for Disease Control and Prevention put out a report outlining a significant spike in Mycoplasma pneumoniae infections, better known as walking pneumonia. This respiratory illness is caused by bacteria spread through respiratory droplets, and symptoms usually mimic the common cold. It's pretty common, with about 2 million infections happening each year, mostly in school-age kids. This year's spike, which started in the spring, is a little different: There's been a significant increase in kids aged 2 to 4 and it is now the new leading cause of pneumonia for that group.Dr. Preeti Sharma, pediatric pulmonologist at Children's Heath in Dallas, knows what it's like to have a child with mycoplasma pneumonia. Her daughter came home with the illness in the spring. What she thought was a typical cold turned into a deep and lingering cough: a telltale sign of walking pneumonia.Dr. Sharma, who is also an associate professor at UT Southwestern, joins Ira Flatow to discuss this year's Mycoplasma pneumoniae spike, the best treatments, and how to keep your family healthy this holiday season. Transcripts for each segment will be available after the show airs on sciencefriday.com. Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.

Vulvar cancer screening refers to checking for signs of vulvar cancer in individuals who may not have symptoms. Vulvar cancer is rare, and there isn't a standard screening test specifically for it like there is for cervical cancer with Pap smears. However, early detection often relies on regular pelvic exams and self-examinations to look for any abnormalities or changes in the vulvar area. Dr. Melissa Mauskar joins me to discuss vulvar screening in this episode.Dr. Melissa Mauskar is a Dermatologist and Associate Professor in the Departments of Dermatology and Obstetrics and Gynecology at UT Southwestern in Dallas, Texas. She is the Director of Genital Dermatology and Women's Health and is an International expert in Lichen Sclerosus and Vulvar dermatoses. Melissa is a fellow of the International Society of the Study of Vulvovaginal Diseases (ISSVD) and the Secretary General of the North American Chapter of the ISSVD. In addition to caring for patients with lichen sclerosus, she is active in clinical research and passionate about patient quality of life and health literacy initiatives. Melissa is the Founding President of the Vulvar Dermatoses Research Consortium (VDRC), an expansive group of healthcare practitioners and trainees in North America dedicated to advancing the field of vulvar health.Featured in this episode: When to see your GYN or healthcare practitioner Look at your vulvar once a month Lichen Scelorus symptoms Check out the vulvar poem here Get Dr. Melissa Mauskar's free e-book on Lichen Scelorus here Listen to the Vulva poem by Dr. Pope hereFollow us on social media: Instagram: @drrpope TikTok: @vulvadoctor Twitter: @drrpope LinkedInWant more from Our Womanity?If you enjoyed this episode of Our Womanity, please subscribe, rate, and leave a review. Your feedback helps us continue to bring you engaging and empowering content.

Dallas' new children's hospital is getting another $100 million donation toward the construction of a $5 billion pediatric care facility, Children's Health and UT Southwestern announced Tuesday; While 1 in 4 women in the United States will experience some form of domestic violence in her lifetime, Langbein said that statistic increases to 1 in 3 in Texas. In Dallas, police statistics show there have been more than 6,600 intimate partner crimes in 2024. Nine were fatal;  Armyworms — named for their tendency to march in troops — have hatched in throngs this fall across North and Central Texas, where they are wreaking havoc. Gardening groups on Facebook are rife with photos of the caterpillars and once-green lawns turned brown. Lawn care companies say they are receiving far more calls than usual, and agricultural organizations have published alerts; and, what makes a taco a great taco? Is it the tortilla? Is it the meat? Is it the salsa? Is it some mysterious secret ingredient?  Surely, you have tried more than one taco in your life. Some have been good, some have not. We asked four North Texas Hispanic restaurateurs to help solve the riddle. These restaurateurs primarily deal in tacos, focusing in on what makes the dish a delicacy worth coming back for more. Learn more about your ad choices. Visit podcastchoices.com/adchoices

The following question refers to Section 2.2 of the 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure.The question is asked by University of Colorado internal medicine resident Dr. Hirsh Elhence, answered first by University of Chicago advanced heart failure cardiologist and Co-Chair for the CardioNerds Critical Care Cardiology Series Dr. Mark Belkin, and then by expert faculty Dr. Mark Drazner.Dr. Drazner is an advanced heart failure and transplant cardiologist, Professor of Medicine, and Clinical Chief of Cardiology at UT Southwestern. He is the President of the Heart Failure Society of America.The Decipher the Guidelines: 2022 AHA / ACC / HFSA Guideline for The Management of Heart Failure series was developed by the CardioNerds and created in collaboration with the American Heart Association and the Heart Failure Society of America. It was created by 30 trainees spanning college through advanced fellowship under the leadership of CardioNerds Cofounders Dr. Amit Goyal and Dr. Dan Ambinder, with mentorship from Dr. Anu Lala, Dr. Robert Mentz, and Dr. Nancy Sweitzer. We thank Dr. Judy Bezanson and Dr. Elliott Antman for tremendous guidance.Enjoy this Circulation 2022 Paths to Discovery article to learn about the CardioNerds story, mission, and values.  Question #35 A 50-year-old woman with a history of congestive heart failure, hypertension, type 2 diabetes mellitus, and obstructive sleep apnea presents to the outpatient clinic to follow up on her heart failure management. One year prior, echocardiogram showed an ejection fraction of 30% with an elevated BNP, for which she was started on appropriate GDMT. Repeat echocardiogram today showed an EF of 50%. Which of the following best describes her heart failure status? A HFrEF (HF with reduced EF) B HFimpEF (HF with improved EF) C HFmrEF (HF with mildly reduced EF) D HFpEF (HF with preserved EF) Answer #35 Explanation The correct answer is B – HFimpEF, or heart failure with improved ejection fraction, best describes her current heart failure status. Left ventricular ejection fraction is an important factor in classifying heart failure given differences in prognosis, response to treatment, and use in clinical trial enrollment criteria. The classification of heart failure by EF (adopted from the Universal Definition of HF): –        HFrEF (HF with reduced EF): LVEF ≤40% –        HFimpEF (HF with improved EF): previous LVEF ≤40%, a ≥10% increase from baseline LVEF, and a second measurement of LVEF >40%. –        HFmrEF (HF with mildly reduced EF): LVEF 41%–49%, andevidence of spontaneous or provokable increased LV filling pressures (e.g., elevated natriuretic peptide, noninvasive and invasive hemodynamic measurement) –        HFpEF (HF with preserved EF): LVEF ≥50%, and evidence of spontaneous or provokable increased LV filling pressures (e.g., elevated natriuretic peptide, noninvasive and invasive hemodynamic measurement) Patients with HFmrEF are usually in a dynamic state of improving from HFrEF or deteriorating towards HFrEF. Therefore, patients with HFmrEF may benefit from follow-up evaluation of systolic function and etiology of sub-normal EF. Improvements in EF are associated with better outcomes but do not indicate full myocardial recovery or normalization of LV function. Indeed, structural and functional abnormalities such as LV dilation and systolic or diastolic dysfunction often persist. Moreover, EF may remain dynamic with fluctuations in either direction depending on factors such as GDMT adherence and re-exposure to cardiotoxic agents. As such, the term heart failure with “improved EF” was deliberately chosen over “recovered EF” and “preserved EF”. Importantly, in patients with HFimpEF while on GDMT, the EF may decrease after withdrawal of GDMT. Main Takeaway

Today I speak with IFBB Bikini Pro Joanna Bolt, a lifelong athlete and full time registered nurse at UT Southwestern in Dallas working with a surgeon in the head & neck cancer clinic. Joanna began competing in 1992 but took many years off before she started competing in Figure in 2005. She won her Pro card in a natural federation in 2010 before taking another hiatus until 2023. She won her IFBB Pro card at 2024 Universe in the over 60 age group. She lives with her best friend, who also happens to be her sister, and has a supportive boyfriend, Scott, as well as a chihuahua mix who is a handful.   TOPICS COVERED -her history in fitness -changes in the past 30 years  -competing at 60 -working as a personal trainer -disordered eating -having a strong faith -community in bodybuilding -being a Masters competitor   CONNECT WITH CELESTE: Website: http://www.celestial.fit Instagram: https://www.instagram.com/celestial_fit/ All Links: http://www.celestial.fit/links.html CONNECT WITH JOANNA: Instagram: https://www.instagram.com/joannabolt_ifbbpro/   TIME STAMPS 1:00 introduction 9:29 getting into body building in the 90's 12:30 coming back after surgery 26:30 overcoming disordered eating 30:39 normalizing bodybuilding 33:36 changing views on fitness 41:05 taking long hiatuses from bodybuilding 45:29 a week in the life 48:15 relationship with her boyfriend 56:30 views on age and competing in Masters 64:10 focuses for the future 67:45 advice for competitors   CLICK HERE TO SIGN UP FOR THE FREE FOOD RELATIONSHIP COACHING SERIES   CLICK HERE TO SIGN UP FOR THE FREE POST SHOW BLUES COACHING SERIES   LEARN MORE AND APPLY FOR MY 5 WEEK FOOD RELATIONSHIP HEALING & DISCOVERY COACHING PROGRAM   FOR OTHER FREE RESOURCES, LIVE EVENTS, AND WAYS TO WORK WITH CELESTE CLICK HERE

What if facing death every day could teach you the true meaning of life? As a transplant doctor, Dr. Weill learned what really matters—discover his journey. Dr. David Weill is the former Director of the Center for Advanced Lung Disease and the Lung and Heart-Lung Transplant Program at Stanford University Medical Center. He is currently the Principal of the Weill Consulting Group, where he focuses on improving the delivery of pulmonary, ICU, and transplant care. Dr. Weill's writing has been featured in prominent publications, including the Wall Street Journal, USA Today, Salon, Newsweek, the Chicago Tribune, STAT, the Washington Post, The Hill, LitHub, Tablet, The Times of Israel, and the Los Angeles Times. He has also appeared on Fox, CNN, and The Doctors television show, and has been interviewed by the New York Times, the San Francisco Chronicle, and the Wall Street Journal. In addition to his extensive professional accomplishments, Dr. Weill is an accomplished author. His memoir, Exhale: Hope, Healing, and A Life in Transplant, was published in May 2021, and his novel, All That Really Matters, was published in June 2024. Dr. Weill attended medical school at Tulane, completed his internal medicine residency at UT Southwestern, and pursued a pulmonary, critical care, and lung transplant fellowship at the University of Colorado. Connect with Dr. Weill LI; @davidweillmd FB: @davidweillmd IG: @davidweillmd

Dr. Paul Sue is an associate professor of pediatrics at the Columbia University and Director of the Pediatric Transplant and Immunocompromised Host or “PITCH” Infectious Diseases Program at the Morgan Stanley Children's Hospital in NY.  He completed his pediatric residency at Jacobi Medical Center at the Albert Einstein College of Medicine in the Bronx, and his fellowship in pediatric infectious diseases at Johns Hopkins University in Baltimore. He then moved to UT Southwestern in Dallas TX, where he served as director of Pediatric ICH ID service for the next 8 years, prior to his recent move back to NY.  His research interests include the impact of invasive fungal and viral infections in the immunocompromised host,  leveraging measures of functional immunity to improve infectious disease outcomes in high-risk patients,  and the emergence of community acquired multidrug resistant (MDR) bacterial infections in immunocompromised children. Sara Dong, MD is an adult and pediatric infectious disease physician at Emory University School of Medicine & Children's Healthcare of Atlanta, where her clinical focus is transplant and immunocompromised host ID.  She earned her MD from the Medical University of South Carolina.  She completed her internal medicine and pediatrics (Med-Peds) residency and chief residency years at Ohio State University Wexner Medical Center and Nationwide Children's Hospital, followed by Med-Peds ID and Medical Education fellowships at Beth Israel Deaconess Medical Center and Boston Children's Hospital.  She is the creator and host of Febrile podcast and learning platform, co-host of the ID Puscast podcast, and the program director for the ID Digital Institute.Learning ObjectivesAfter listening to this episode on invasive candidemia, learners should be able to discuss:Treatment of candidemia in a critically-ill immunocompromised patient.Management of indwelling central catheters in critically-ill patients with candidemia.The role of immune adjuncts (e.g. G-CSF or granulocyte transfusions) in the management of persistent candidemia in an immunocompromised patient.References:https://febrilepodcast.com/ Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, Reboli AC, Schuster MG, Vazquez JA, Walsh TJ, Zaoutis TE, Sobel JD. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update bQuestions, comments or feedback? Please send us a message at this link (leave email address if you would like us to relpy) Thanks! -Alice & ZacSupport the Show.How to support PedsCrit:Please complete our Listener Feedback SurveyPlease rate and review on Spotify and Apple Podcasts!Donations are appreciated @PedsCrit on Venmo , you can also support us by becoming a patron on Patreon. 100% of funds go to supporting the show. Thank you for listening to this episode of PedsCrit. Please remember that all content during this episode is intended for educational and entertainment purposes only. It should not be used as medical advice. The views expressed during this episode by hosts and our guests are their own and do not reflect the official position of their institutions. If you have any comments, suggestions, or feedback-you can email us at pedscritpodcast@gmail.com. Check out http://www.pedscrit.com for detailed show notes. And visit @critpeds on twitter and @pedscrit on instagram for real time show updates.

Dr. Paul Sue is an associate professor of pediatrics at the Columbia University and Director of the Pediatric Transplant and Immunocompromised Host at the Morgan Stanley Children's Hospital in NY.  He completed his pediatric residency at Jacobi Medical Center at the Albert Einstein College of Medicine in the Bronx, and his fellowship in pediatric infectious diseases at Johns Hopkins University in Baltimore. He then moved to UT Southwestern in Dallas TX, where he served as director of Pediatric ICH ID service for the next 8 years, prior to his recent move back to NY.  His research interests include the impact of invasive fungal and viral infections in the immunocompromised host,  leveraging measures of functional immunity to improve infectious disease outcomes in high-risk patients,  and the emergence of community acquired multidrug resistant (MDR) bacterial infections in immunocompromised children. Sara Dong, MD is an adult and pediatric infectious disease physician at Emory University School of Medicine & Children's Healthcare of Atlanta, where her clinical focus is transplant and immunocompromised host ID.  She earned her MD from the Medical University of South Carolina.  She completed her internal medicine and pediatrics (Med-Peds) residency and chief residency years at Ohio State University Wexner Medical Center and Nationwide Children's Hospital, followed by Med-Peds ID and Medical Education fellowships at Beth Israel Deaconess Medical Center and Boston Children's Hospital.  She is the creator and host of Febrile podcast and learning platform, co-host of the ID Puscast podcast, and the program director for the ID Digital Institute.Learning ObjectivesAfter listening to this episode on invasive candidemia, learners should be able to discuss:Risk factors associated with invasive fungal infections in critically-ill immunocompromised patients.Common pathogens associated with invasive fungal infections in critically-ill immunocompromised patients.Principles guiding selection of empiric antifungal agents for critically-ill patients at risk of invasive fungal infections.References:https://febrilepodcast.com/ Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, Reboli AC, Schuster MG, Vazquez JA, Walsh TJ, Zaoutis TE, Sobel JD. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the InfQuestions, comments or feedback? Please send us a message at this link (leave email address if you would like us to relpy) Thanks! -Alice & ZacSupport the Show.How to support PedsCrit:Please complete our Listener Feedback SurveyPlease rate and review on Spotify and Apple Podcasts!Donations are appreciated @PedsCrit on Venmo , you can also support us by becoming a patron on Patreon. 100% of funds go to supporting the show. Thank you for listening to this episode of PedsCrit. Please remember that all content during this episode is intended for educational and entertainment purposes only. It should not be used as medical advice. The views expressed during this episode by hosts and our guests are their own and do not reflect the official position of their institutions. If you have any comments, suggestions, or feedback-you can email us at pedscritpodcast@gmail.com. Check out http://www.pedscrit.com for detailed show notes. And visit @critpeds on twitter and @pedscrit on instagram for real time show updates.

The following question refers to Sections 6.1 and 7.4 of the 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure.The question is asked by University of Colorado internal medicine resident Dr. Hirsh Elhence, answered first by University of Chicago advanced heart failure cardiologist and Co-Chair for the CardioNerds Critical Care Cardiology Series Dr. Mark Belkin, and then by expert faculty Dr. Mark Drazner.Dr. Drazner is an advanced heart failure and transplant cardiologist, Professor of Medicine, and Clinical Chief of Cardiology at UT Southwestern. He is the President of the Heart Failure Society of America.The Decipher the Guidelines: 2022 AHA / ACC / HFSA Guideline for The Management of Heart Failure series was developed by the CardioNerds and created in collaboration with the American Heart Association and the Heart Failure Society of America. It was created by 30 trainees spanning college through advanced fellowship under the leadership of CardioNerds Cofounders Dr. Amit Goyal and Dr. Dan Ambinder, with mentorship from Dr. Anu Lala, Dr. Robert Mentz, and Dr. Nancy Sweitzer. We thank Dr. Judy Bezanson and Dr. Elliott Antman for tremendous guidance.Enjoy this Circulation 2022 Paths to Discovery article to learn about the CardioNerds story, mission, and values. /*! elementor - v3.23.0 - 25-07-2024 */ .elementor-toggle{text-align:start}.elementor-toggle .elementor-tab-title{font-weight:700;line-height:1;margin:0;padding:15px;border-bottom:1px solid #d5d8dc;cursor:pointer;outline:none}.elementor-toggle .elementor-tab-title .elementor-toggle-icon{display:inline-block;width:1em}.elementor-toggle .elementor-tab-title .elementor-toggle-icon svg{margin-inline-start:-5px;width:1em;height:1em}.elementor-toggle .elementor-tab-title .elementor-toggle-icon.elementor-toggle-icon-right{float:right;text-align:right}.elementor-toggle .elementor-tab-title .elementor-toggle-icon.elementor-toggle-icon-left{float:left;text-align:left}.elementor-toggle .elementor-tab-title .elementor-toggle-icon .elementor-toggle-icon-closed{display:block}.elementor-toggle .elementor-tab-title .elementor-toggle-icon .elementor-toggle-icon-opened{display:none}.elementor-toggle .elementor-tab-title.elementor-active{border-bottom:none}.elementor-toggle .elementor-tab-title.elementor-active .elementor-toggle-icon-closed{display:none}.elementor-toggle .elementor-tab-title.elementor-active .elementor-toggle-icon-opened{display:block}.elementor-toggle .elementor-tab-content{padding:15px;border-bottom:1px solid #d5d8dc;display:none}@media (max-width:767px){.elementor-toggle .elementor-tab-title{padding:12px}.elementor-toggle .elementor-tab-content{padding:12px 10px}}.e-con-inner>.elementor-widget-toggle,.e-con>.elementor-widget-toggle{width:var(--container-widget-width);--flex-grow:var(--container-widget-flex-grow)} Question #34 Question StemA 72-year-old woman with a history of hypertension, type 2 diabetes mellitus, and a recent myocardial infarction is seen in your clinic. Two months previously, she was hospitalized with a myocardial infarction and underwent successful revascularization of the left anterior descending artery with a drug-eluting stent. Following her myocardial infarction, an echocardiogram revealed an ejection fraction of 17%, and she was discharged on metoprolol succinate, lisinopril, spironolactone, and dapagliflozin with escalation to maximal tolerated doses over subsequent visits. A repeat echocardiogram performed today in your clinic reveals an ejection fraction of 26%. An electrocardiogram reveals normal sinus rhythm with a narrow QRS at a heart rate of 65 beats per minute. She is grateful for her cardiac rehabilitation program and reports no ongoing symptoms. Which of the following devices is indicated for placement at this time?Answer choicesAImplantable loop recorderBICDCCRT-DDCRT-P Answer #34 Explanation The correct answer is B.

What is the best way to manage an infected thyroglossal duct cyst? In this episode, hosts Dr. Gopi Shah and Dr. Ashley Agan welcome Dr. Christopher Liu, associate professor of pediatric otolaryngology at UT Southwestern, to learn about his vast experience with evaluation and management of thyroglossal duct cysts and the nuances of other congenital neck masses. --- CHECK OUT OUR SPONSOR Medtronic ENT https://www.medtronic.com/us-en/healthcare-professionals/medical-specialties/ear-nose-throat.html?cmpid=Vanity_URL_MIX_medtronicent-com_202212_US_EN_NS_ENT_FY23 --- SYNPOSIS First, Dr. Liu describes how thyroglossal duct cysts present. Patients often become aware of their cyst when a parent palpates a midline neck mass or when the cyst gets infected. Then, Dr. Liu describes non-operative management of thyroglossal duct cysts, including antibiotics to treat infection and cases in which drainage is appropriate. The conversation proceeds to surgical strategy, with Dr. Liu describing how his approach to cyst excision evolved over the years. The episode concludes with pearls on post-operative management and potential surgical complications. --- TIMESTAMPS 00:00 - Introduction 02:53 - Understanding Thyroglossal Duct Cysts 11:48 - Managing Infected Thyroglossal Duct Cysts 14:02 - Antibiotic Choices & Drainage Techniques 21:05 - Imaging & Workup 25:39 - Surgical Approach and Techniques 27:29 - Koempel's Technique for Thyroglossal Duct Cyst Surgery 39:04 - Surgical Complications, Risk of Recurrence, & Post-Operative Care 52:37 - Key Takeaways for Thyroglossal Duct Cyst Surgery --- RESOURCES Dr. Christopher Liu's UT Southwestern Profile: https://utswmed.org/doctors/christopher-liu/ Jeffrey Koempel, “Thyroglossal Duct Remnant Surgery: A Reliable, Reproducible Approach to the Suprahyoid Region”: https://pubmed.ncbi.nlm.nih.gov/25193588/

Download the 13-Page "Omega-3 Supplementation Guide" Discover my premium podcast, The Aliquot Join over 300,000 people and sign up for my newsletter Become a FoundMyFitness premium member to get access to exclusive episodes, emails, live Q+A's with Rhonda and more Everyone has to get old sometime, but what if, at least for some aspects of aging, we didn't have to? Imagine if the loss of heart size and the stiffness that often comes with aging could be reversed, even well into late middle-age. And not by a little - by a lot. Today's guest, Dr. Benjamin Levine, has shown that with the right exercise protocol, people who were sedentary most of their lives could reverse up to 20 years of heart aging. Dr. Levine is one of the world's leading experts in understanding how the heart adapts under a variety of conditions, whether that's exercise, elite athleticism, or hospital bedrest. Or even highly exotic conditions, like prolonged exposure to microgravity. He is the founding director of the Institute for Exercise and Environmental Medicine at UT Southwestern in Dallas, a leading facility renowned for its research in cardiovascular physiology. His expertise also extends into space medicine, where he advises NASA, underscoring his broad, deeply fundamental understanding of how the heart changes over time. Additionally, he is a recognized authority in sports cardiology, consulting for organizations such as the NCAA, NFL, NHL, and various professional sports leagues. In this episode, we discuss: (00:06:21) Are 3 weeks of bed rest worse for fitness than 30 years of aging? (00:10:08) Why untrained individuals recover fitness faster than athletes following bed rest (00:11:40) Does exercise protect against long COVID? (00:14:31) "COVID triad testing" guidelines for evaluating heart health in athletes (00:16:17) Why strict bed rest is a model for space flight (00:17:14) How 12 weeks of bed rest affects heart size (00:18:42) Why a brand-new rubber band mimics a lifetime of endurance training (00:22:14) The exercise dose that preserves youthful cardiovascular structure (00:24:22) The exercise regimen that reversed 20 years of heart aging (00:28:05) What it takes to reverse vascular age by 15 years in 70-year-olds (00:33:29) Benefits of starting an exercise regimen in your 70s [benefits that don't involve cardiac remodeling] (00:39:17) Considering the risks of high-intensity exercise (00:42:42) Balancing high-intensity & moderate-intensity training (00:47:39) Training for health vs. training for performance (00:48:47) Why muscle mass & cardiorespiratory fitness are like retirement funds (00:49:58) Make exercise a part of your personal hygiene (00:51:01) Why does VO2 max correlate with longevity? (00:58:29) The 2018 JAMA study on cardiorespiratory fitness & mortality (01:04:06) How does change in fitness over time affect mortality? (01:06:19) Why exercise non-responders should consider "increasing the dose" (01:10:08) The 2 limiting factors for improving VO2 max in competitive athletes (01:13:05) How marathon training affects heart size in sedentary young people (01:17:20) Heart adaptations in purely strength-trained vs. endurance athletes (01:23:09) Why pure strength-trainers should incorporate endurance training (01:26:53) How strength training affects blood pressure (exercise pressor reflex) (01:31:27) How exercise influences cardiac output in mitochondrial myopathy patients (01:33:25) Does CrossFit count as endurance training? (01:35:50) What's the best exercise for improving blood pressure? (01:40:57) Lifestyle strategies for treating hypertension (01:43:26) Why recovery is key to reaping the benefits of a training stimulus (01:47:22) The best indicator of being overtrained (01:48:22) Heart rate brackets & running pace estimates for training zones 2-5 (01:54:46) Why heart rate variability is a poor indicator of recovery (02:00:02) Why do men tend to be faster runners than women? (02:03:34) Can women achieve similar aerobic exercise benefits doing 2x less than men? (02:05:06) Are there cardiovascular benefits of HRT in women? (02:06:57) How Dr. Benjamin Levine defines "extreme exercise" (02:08:45) How does exercise volume affect coronary plaque calcification (02:15:35) How exercise duration & intensity affect coronary calcium levels (02:18:48) Why high exercise duration & intensity increases risk of Afib (02:21:18) What exercise dose increases Afib risk? (02:23:06) Managing stroke risk in athletes prone to Afib with anticoagulants (02:26:00) Why you shouldn't become an endurance athlete to "live longer" Watch this episode on YouTube

CardioNerds (Drs. Gurleen Kaur and Richard Ferraro) and episode FIT Lead Dr. Spencer Carter (Cardiology Fellow at UT Southwestern) discuss the clinical implementation of GLP-1 receptor agonists with Dr. Neha Pagidapati (Faculty at Duke University School of Medicine). In this episode of the CardioNerds Cardiovascular Prevention Series, we discuss the clinical implementation of glucagon-like peptide-1 (GLP-1) receptor agonists. We cover the clinical indications, metabolic and cardiovascular benefits, and potential limitations of these emerging and exciting therapies. Show notes were drafted by Dr. Spencer Carter. Audio editing was performed by CardioNerds Academy Intern, student Dr. Pacey Wetstein. This episode was produced in collaboration with the American Society of Preventive Cardiology (ASPC) with independent medical education grant support from Novo Nordisk. See below for continuing medical education credit. Claim CME for this episode HERE. CardioNerds Prevention PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Pearls and Quotes - Clinical Implementation of GLP-1 Receptor Agonists GLP-1 agonists work through a variety of mechanisms to counteract metabolic disease. They increase insulin secretion, inhibit glucagon secretion, slow gastric motility, and increase satiety to limit excess energy intake. Patients with type II diabetes and an elevated risk for atherosclerotic cardiovascular disease should be considered for GLP-1 agonist therapy regardless of hemoglobin A1c. GLP-1 agonists offer significant ASCVD risk reduction even in the absence of diabetes. Newer data suggest a significant reduction in cardiovascular events with GLP-1 agonist therapy in patients who are overweight or obese and have a prior history of heart disease. GLP-1 agonists should generally be avoided in patients with a history of medullary thyroid cancer or MEN2. As these medications slow gastric emptying, relative contraindications include history of recurrent pancreatitis and gastroparesis. GLP-1 agonists should be initially prescribed at the lowest dose and slowly uptitrated to avoid gastrointestinal side effects. Show notes - Clinical Implementation of GLP-1 Receptor Agonists What were the groundbreaking findings of the STEP1 and SURMOUNT-1 trials and how these impact cardiovascular wellness? The STEP1 and SURMOUNT trials demonstrated sustained clinically relevant reduction in body weight with semaglutide and tripeptide, respectively, in patients with overweight and obesity. As obesity is an important risk factor for the development of cardiovascular disease, weight reduction meaningfully contributes to cardiovascular wellness. What were the findings of the LEADER trial and their implications for patients with type II diabetes and high cardiovascular risk? The LEADER trial demonstrated a significant reduction in the rate of cardiovascular death, nonfatal MI, or nonfatal stroke in patients with type II diabetes treated with liraglutide. GLP-1 receptor agonist therapy should be considered in all patients with type II diabetes and elevated ASCVD risk regardless of A1c or current hyperglycemic therapy. What are current indications for GLP1 agonists in the context of cardiometabolic disease. GLP-1 receptor agonists should be considered in patients with type II diabetes and high ASCVD risk OR patients without diabetes who are overweight/obese and have a history of cardiovascular disease. What are important side effects or contraindications to GLP1 agents when used for cardiovascular risk reduction and wellness? GLP-1 receptor agonists should be avoided in patients with a history of medullary thyroid cancer or MEN2. Relative contraindications include recurrent pancreatitis, gastroparesis,